Next Article in Journal
The Involvement of Endothelin-1 in Sepsis and Organ Dysfunction—A Novel Biomarker in Patient Assessment
Previous Article in Journal
Dissociation of Clinical Outcomes and CSF Proteinopathy Biomarkers in Parkinson’s Disease: Cognitive–Affective Dissociation with Specificity for Tau
Previous Article in Special Issue
Cold vs. Room Temperature: A Comparative Analysis of Platelet Functionality in Cold Storage
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Biomedicines
Volume 13
Issue 10
10.3390/biomedicines13102479
biomedicines-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Review

α-Actinin-1 in Megakaryocytes: Its Structure, Interacting Proteins and Implications for Thrombopoiesis

by
Lanlan Wu
1,
Zhiqun Song
2,
Yulan Zhou
3,
Jiansong Huang
4,* and
Xiaoxia Huang
1,*
1
Department of Nursing, Department of Emergency Medicine, The Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou 310003, China
2
Department of Blood Transfusion, Jiangsu Province People’s Hospital and the First Affiliated Hospital of Nanjing Medical University, Nanjing 210029, China
3
Department of Hematology, The First Affiliated Hospital of Nanchang University, Nanchang 330006, China
4
Key Laboratory of Hematologic Malignancies, Diagnosis and Treatment, Department of Hematology, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou 310003, China
*
Authors to whom correspondence should be addressed.
Biomedicines 2025, 13(10), 2479; https://doi.org/10.3390/biomedicines13102479
Submission received: 17 August 2025 / Revised: 7 October 2025 / Accepted: 9 October 2025 / Published: 11 October 2025
(This article belongs to the Special Issue Platelets in Health and Disease: From Molecular Mechanisms to Therapeutic Potential)
Browse Figures
Versions Notes

Abstract

Mutations in the ACTN1 gene, which encodes the cytoskeletal protein α-actinin-1, have been implicated in the etiology of autosomal dominant congenital macrothrombocytopenia. α-Actinin-1 is a member of the spectrin superfamily and is essential for key physiological processes in megakaryocytes and platelets. The pathophysiological mechanisms by which α-actinin-1 mutations lead to macrothrombocytopenia have been attributed to alterations in actin organization, increased binding affinity of α-actinin-1 to actin filaments, and modulation of integrin αIIbβ3 signaling. In previous studies, we utilized megakaryocyte-specific α-actinin-1 knockout (PF4-ACTN1−/−) mice to explore the influence of α-actinin-1 on megakaryocyte and platelet function. Despite these efforts, the precise mechanisms remain inadequately understood. To advance our understanding and clarify the role of α-actinin-1 in thrombopoiesis, we first delineated the functions of α-actinin-1 in megakaryocytes and platelets, followed by a comprehensive overview of the proteins known to interact with α-actinin-1. As a pivotal scaffold protein, α-actinin-1 interacts with a complex network of partners, including integrin αIIbβ3, and actin filaments, to modulate cytoskeletal dynamics, megakaryocyte maturation, and proplatelet formation. In addition to its well-documented proteins that interact with α-actinin-1 within megakaryocytes and platelets, α-actinin-1 also associates with proteins outside the megakaryocytic lineage, such as cytohesin-2 and MOB1, which have been predominantly examined in other cellular contexts. These varied interactions imply that α-actinin-1 may influence megakaryocyte and platelet functions through multiple mechanisms. This review provides a comprehensive synthesis of current knowledge regarding the structure, binding partners of α-actinin-1, and essential roles of α-actinin-1 in thrombopoiesis.

1. Introduction

Inherited thrombocytopenia is a highly heterogeneous disorder primarily attributed to genetic abnormalities affecting megakaryocytes (MKs) and platelets [1,2]. Clinically, this condition is characterized by a decreased platelet count and compromised platelet function, which may result in impaired hemostasis [1]. To date, mutations responsible for inherited thrombocytopenia have been identified in more than 30 genes. These genes are categorized into six groups on the basis of their subcellular localization and function: (1) genes related to cytoskeletal components [3,4,5,6,7,8,9,10]; (2) genes associated with glycoprotein adhesion receptors [11,12,13,14]; (3) genes related to transcription factors [15,16,17,18,19,20,21]; (4) genes involved in platelet granules [22,23]; (5) genes related to signal transduction [24,25,26,27,28]; and (6) other genes, including ABCG5/ABCG8, RBM8A, and ANKRD26 [29,30,31]. Inherited thrombocytopenia is categorized into three subgroups on the basis of the mean platelet volume: large, normal, or small. Among these, congenital macrothrombocytopenia (CMTP) is particularly significant and is characterized by the presence of large platelets and reduced platelet counts. Recent studies have identified abnormalities in the ACTN1 gene as a contributing factor to CMTP [32,33,34,35,36,37,38,39]. Patients with these genetic aberrations typically exhibit decreased platelet counts, increased platelet volumes, and minor impairments in certain platelet functions, such as a 37% reduction in adenosine diphosphate (ADP)-induced aggregation, whereas collagen- and ristocetin-induced aggregation remains unaffected. The clinical manifestations range from asymptomatic to severe bleeding [36]. In a study of 13 Japanese CMTP pedigrees, ACTN1 gene mutations were identified in six pedigrees (46%) [32]. These mutations represent the fourth most common cause of CMTP in the Japanese population, accounting for 5.5% of cases [32]. The ACTN1 gene encodes the protein α-actinin-1. This review provides a comprehensive overview of the current knowledge regarding α-actinin-1 in MKs, including its fundamental structure, associated binding proteins, and pivotal role in thrombopoiesis. The term ‘α-actinin-1’ refers specifically to this isoform, whereas the general term ‘α-actinin’ is used when unspecified isoforms from earlier research are cited.

2. Thrombopoiesis

Platelets play important roles in physiological and pathological processes, such as hemostasis, thrombosis, inflammation, and tumor metastasis [40]. These enucleated cell fragments are derived from MKs, with each MK capable of producing approximately 1000 to 3000 platelets. The production of platelets can be conceptually divided into two distinct stages. The initial stage involves the maturation of MKs. According to the classical model of megakaryopoiesis, hematopoietic stem cells (HSCs), which are located in the osteoblastic niche—a proliferative microenvironment within the bone marrow (BM)—differentiate into MK-erythroid progenitor cells, which subsequently evolve into distinct MK progenitor cells [41]. Under regulation by chemokines, growth factors (primarily thrombopoietin), stromal cells, and other regulatory factors, MK progenitor cells differentiate into mature MKs (stage III MKs) through two intermediary stages: megakaryoblasts (stage I MKs) and promegakaryocytes (stage II MKs), thereby preparing for platelet production [42]. Furthermore, recent studies have proposed an alternative model suggesting the presence of MK/platelet-biased HSCs within the HSC population [43,44,45]. During the process of MK maturation, these cells undergo significant enlargement accompanied by extensive nuclear proliferation and the biosynthesis of platelet-specific granules. Additionally, MKs expand their cytoplasmic contents and develop a demarcation membrane system (DMS) to facilitate the formation of the plasma membranes necessary for platelet production [46]. The subsequent stage encompasses proplatelet formation and platelet release, which occur within several hours. Under regulation by stromal cell-derived factor 1-α (SDF-1α) signaling, mature MKs (ranging from 8 to 64 N ploidy) migrate from the BM niche to the capillary-rich vascular niche and the lung microcirculation, where they extend their cytoplasm to form branched structures known as proplatelets [47,48]. Under conditions of shear and turbulent flow, platelets are subsequently released from these proplatelets into the circulation [49]. Figure 1 shows a schematic of the process of MK maturation, polyploidization, and platelet production.
The microtubule system underpins the extensions of proplatelets and the discoid shape of platelets. In contrast, the actin filament system in nonactivated platelets remains inactive. However, platelet activation triggers a dynamic reorganization of the actin filament system, which facilitates morphological changes in response to external stimuli. Cytoskeletal reorganization plays a crucial role not only in the induction of proplatelet formation and platelet release from MKs but also in ensuring the proper functionality of platelets within the circulatory system. Cytoskeleton rearrangement facilitates the redistribution of organelles and granular components within the MK cytoplasm and promotes the extension of the cytoplasm to form proplatelets, which ultimately release platelets. The functions of platelets, including spreading, aggregation, clot retraction, and the release of granular contents, are also dependent on cytoskeletal rearrangement. Cytoskeletal proteins determine the structures of MKs and platelets, as well as their capacity to respond to various stimuli. Accumulating evidence suggests that the actin filament-based cytoskeleton [50] and certain actin-binding proteins, such as twinfilin 2a [51], cofilin 1 [52], filamin A [53], L-plastin [41], dematin [54] and nonmuscle myosin IIA [55], and controlling cytoskeletal dynamic proteins, such as Rho GTPases [56,57], play critical pathophysiologic roles in megakaryopoiesis, platelet biogenesis, and function. Mutations or deletions in genes encoding cytoskeletal-related proteins can lead to conditions such as CMTP [58]. Specifically, mutations in the MYH9 gene, which encodes nonmuscle myosin heavy chain IIA, result in macrothrombocytopenia [58,59]. Mutations in the PLNA gene are associated with reduced platelet counts, increased platelet volumes, and enlarged α granules [60]. Furthermore, genes such as TUBB1 [61], WASP [62], DIAPH1 [63], TRPM7 [10], TMP4 [64], and ACTN1 [35] influence platelet production and function through reorganization of the cytoskeleton. Specifically, mutations in the actin-binding domain (ABD), rod domain, and calmodulin-like domain (CaMD) of α-actinin-1 result in the loss of normal function, leading to CMTP [32,33,34,35,36,38,39]. Motoko et al. recently reported that an SLR2 mutation (L395Q) in α-actinin-1 is responsible for CMTP [36].

3. The Role of α-Actinin-1 in MKs and Platelets

The understanding of α-actinin-1 functions within MKs has undergone significant evolution over time. Initial investigations focused predominantly on the general role of cytoskeletal proteins in MKs. However, advancements in molecular biology techniques have facilitated more detailed examinations of the specific functions of α-actinin-1 in MK biology. In 2007, Raslova et al. employed a gene profiling approach to demonstrate that the expression of the ACTN1 gene is upregulated during polyploidization and MK differentiation [65]. Furthermore, α-actinin has been identified as essential for the regulation of cytokinesis in both yeast and mammalian cells [66]. In 1978, Fujiwara et al. first demonstrated that α-actinin localizes to the cleavage furrow alongside myosin during cytokinesis in mammalian cells, suggesting that it plays a role in anchoring the contractile ring to the plasma membrane [67]. In 2013, Elagib et al. revealed that the knockdown of α-actinin-1 resulted in reduced megakaryocytic polyploidization [68]. The expression of α-actinin-1 is upregulated during MK differentiation through the activation of calpain 2, which in turn activates the positive transcription elongation factor b (p-TEFb) pathway, underscoring its critical role in terminal megakaryopoiesis and platelet biogenesis [68]. In the same year, a pivotal historical discovery was made with the identification of mutations in α-actinin-1 among patients with CMTP [32]. This discovery was significant, as it established a direct association between α-actinin-1 and disorders related to MKs. Among the MKs, α-actinin-1 plays a critical role in the crosslinking of actin filaments, a process essential for maintaining proper actin filament-based cytoskeleton structure and facilitating dynamic remodeling during proplatelet formation. Proplatelet formation is the mechanism by which MKs extend cytoplasmic projections that subsequently fragment into platelets. Mutations in the ACTN1 gene associated with CMTP disrupt normal actin bundling, resulting in a disorganized actin filament-based cytoskeleton. This structural defect leads to abnormal proplatelet morphology, characterized by fewer but larger proplatelet tips, which correlates with the production of fewer and larger platelets, a condition known as macrothrombocytopenia, in affected individuals. Therefore, α-actinin-1 is indispensable for efficient platelet production and the maintenance of actin filament-based cytoskeleton integrity in MKs.
α-Actinin-1 plays critical roles in both MKs and platelets, primarily through its function as an actin crosslinking protein that regulates cytoskeletal dynamics. In MKs, α-actinin-1 is involved in endomitosis, a process essential for polyploidization and maturation [68,69]. It contributes to the formation of the contractile ring during cytokinesis, and its dysregulation can lead to defective polyploidization and impaired MK enlargement. Additionally, α-actinin-1 is implicated in proplatelet formation, where it helps regulate the branching and extension of proplatelets. Mutations in α-actinin-1 result in reduced proplatelet tip numbers and increased tip size, ultimately leading to macrothrombocytopenia [32,39].
In platelets, α-actinin-1 is crucial for activation, adhesion, and shape changes. It facilitates actin filament bundling in pseudopods and filopodia during platelet activation, and its phosphorylation status modulates interactions with integrins such as αIIbβ3, influencing platelet aggregation and the response to shear stress. α-Actinin-1 also anchors signaling complexes with GPIb-IX-V, contributing to platelet adhesion under flow conditions [70]. Furthermore, it localizes to actin nodules and podosome-like structures, enhancing platelet aggregate stability [71]. Its ability to sense mechanical forces and regulate cytoskeletal reorganization underscores its importance in both platelet production and function.
Our study utilized MK-specific α-actinin-1 knockout (platelet factor 4 (PF4)-ACTN1−/−) mice and demonstrated that these mice presented with reduced platelet counts, compromised platelet functionality, diminished thrombus formation, and impaired mitochondrial activity [72]. In these mice, there is a reduction in the number of MKs within the BM, accompanied by abnormalities in MK ploidy, characterized by an increased proportion of 2–4 N MKs and a decreased proportion of 8–32 N MKs [72]. Furthermore, PF4-ACTN1−/− platelets exhibit reduced spreading, clot retraction, aggregation, integrin αIIbβ3 activation, and P-selectin exposure in response to various agonists [72].

4. The Structure and Expression of α-Actinin-1

α-Actinin-1 is a cytoskeletal protein belonging to the spectrin superfamily of actin-binding proteins [32,73]. Among the four identified α-actinin isoforms, α-actinin-1 is categorized as a nonmuscle isoform because of its extensive expression in nonmuscle cells and its sensitivity to calcium. Structurally, α-actinin-1 has a conserved domain architecture characteristic of all α-actinin isoforms: it possesses an N-terminal actin-binding domain (ABD) comprising two calponin homology (CH) domains (CH1 and CH2), a connecting segment (neck), a central rod domain composed of four spectrin repeats (SR1–SR4) that facilitate antiparallel dimerization, and a C-terminal calmodulin-like (CaM) domain containing E-helix and F-helix (EF)-hand motifs (Figure 2). The protein functions as an antiparallel homodimer, enabling it to crosslink actin filaments at both ends, thereby contributing to the organization and stability of the actin cytoskeleton. The actin-binding domain (ABD) region encompasses at least three primary actin-binding sites (ABSs) and facilitates the cross-linking of actin filaments at a 1:10 ratio within bundles [74,75]. Additionally, the ABD region can engage in direct or indirect interactions with integrins. Specifically, the ABD of α-actinin-1 is crucial for F-actin binding, with significant actin-binding sites located within the CH1 domain and the linker region between CH1 and CH2. The central rod domain plays a role in dimerization and imparts structural stability, whereas the CaM domain modulates actin-binding activity in a calcium-dependent fashion. The CaMD region comprises four EF-hand motifs (EF1/2 and EF3/4) [32,76], which have the capacity to bind calcium ions. In nonmuscle isoforms, such as α-actinin-1, the binding of calcium induces conformational changes that influence the efficiency of actin crosslinking.
In mammals, the α-actinin family comprises four members: α-actinin-1 (MIM 102575, human chromosome 14q24.1), α-actinin-2 (MIM 102573, human chromosome 1q43), α-actinin-3 (MIM 102574, human chromosome 11q13.2), and α-actinin-4 (MIM 604638, human chromosome 19q13.2) [77]. These α-actinins are categorized into two distinct classes on the basis of their sensitivity to calcium ions (Ca2+): Ca2+-sensitive and Ca2+-insensitive [77]. Specifically, α-actinin-1 and α-actinin-4 exhibit Ca2+ sensitivity and are broadly expressed in nonmuscle cells, whereas α-actinin-2 and α-actinin-3 are Ca2+-insensitive and predominantly localized to muscle cells [77]. α-Actinin-1 is ubiquitously expressed across various tissues, including platelets, endothelial cells, fibroblasts, and epithelial cells. It is localized to stress fibers, focal adhesions, and adherens junctions, where it functions as a crucial scaffold linking the actin filament-based cytoskeleton to transmembrane receptors such as integrins and cell adhesion molecules. In platelets, α-actinin-1 is particularly abundant and plays vital roles in platelet activation, aggregation, and MK maturation. Its expression and subcellular localization are dynamically regulated during cellular processes such as migration, adhesion, and cytokinesis.
Mutations in the ACTN1 gene frequently result in either an increased affinity for actin binding or a disruption of structural integrity, culminating in actin filament-based cytoskeleton disorganization and compromised platelet functionality. Furthermore, the expression of α-actinin-1 is subject to modulation in various cancers, although its precise role in oncogenesis is not as well understood as that of α-actinin-4 [73]. Overall, α-actinin-1 is a multifunctional protein that plays a critical role in actin filament-based cytoskeleton dynamics, mechanical stability, and cellular signaling, with its expression and function being meticulously regulated across diverse cell types and physiological contexts. Several comprehensive reviews have provided an in-depth examination of the structure and functions of α-actinins [73,75,78,79,80]. The binding partners that can interact with α-actinin-1 are detailed in Table 1 and Table 2.

5. Proteins That Interact with α-Actinin-1

5.1. Integrin αIIbβ3 (Also Known as Glycoprotein GPIIb/IIIa)

Integrin αIIbβ3, comprising the integrin αIIb and β3 subunits, serves as the principal membrane receptor in MKs and platelets, facilitating rapid and bidirectional signal transduction across the plasma membrane [40,103]. In its resting state, integrin αIIbβ3 adopts an inactive conformation. Upon stimulation of platelets by various agonists, including thrombin, ADP, thromboxane A2 (TXA2), and collagen, integrin αIIbβ3 undergoes inside-out signaling, also referred to as integrin αIIbβ3 activation. The binding of activated integrin αIIbβ3 to its ligand initiates outside-in signaling and promotes integrin αIIbβ3 clustering, ultimately triggering a cascade of intracellular signaling events. These events include the phosphorylation of Y747, T753, and Y759 in the cytoplasmic tail of integrin β3; the activation of Src family kinases (SFKs) and spleen tyrosine kinase (Syk); and the subsequent activation of downstream signaling pathways associated with SFKs and Syk [40,104]. Current models suggest that Syk interacts with immunoreceptor tyrosine-based activation motif (ITAM)-containing receptors that interact, in turn, with the integrin [105]. Integrin αIIbβ3 outside-in signaling is also important for thrombopoiesis, including MK maturation and proplatelet formation [46,106]. The structure, signaling, and function of integrin αIIbβ3 have been summarized in several comprehensive reviews [40,104,107,108,109,110], which can be referenced further.
The bidirectional signal transduction of integrin αIIbβ3 is thought to be mediated by direct or indirect interactions of integrin αIIbβ3 cytoplasmic tails with intracellular signaling proteins. The cytoplasmic tail of human integrin β3 is longer than the cytoplasmic tail of human integrin αIIb and contains three key amino acid residues, namely, tyrosine Y747, threonine T753, and tyrosine Y759, which can be phosphorylated [111,112,113]. Considerable progress in understanding the proteins that interact with integrin αIIbβ3 cytoplasmic tails and regulate the bidirectional signaling of integrin αIIbβ3 has been achieved in recent years. For example, vacuolar protein sorting-associated protein 33B (VPS33B) [114], talin rod [115], Src [116,117], and Gα13 [118,119] are involved in integrin αIIbβ3 outside-in signaling, and integrin-linked kinase (ILK) [120], β3-endonexin [121], talin head [122], and kindlin-3 [123] participate in integrin αIIbβ3 inside-out signaling. Notably, phosphorylation of T753, Y747, and Y759 in the integrin β3 cytoplasmic tail can affect interactions between the integrin β3 cytoplasmic tail and intracellular signaling proteins, which further regulate integrin αIIbβ3 bidirectional signal transduction. Phosphorylation of T753 on the TST753 motif of the integrin β3 cytoplasmic tail can interfere with the binding of the Shc protein and SH2-containing proteins to the integrin β3 cytoplasmic tail [113]. Thrombin stimulation can cause Y747 and Y759 phosphorylation in the integrin β3 cytoplasmic tail in platelets. Some questions remain regarding the molecular mechanism by which α-actinin-1 regulates integrin αIIbβ3 bidirectional signal transduction; for example, does tyrosine phosphorylation of the integrin β3 cytoplasmic tail affect the interaction between the integrin β3 cytoplasmic tail and α-actinin-1 in integrin αIIbβ3 bidirectional signal transduction?
α-Actinin-1 is involved in the bidirectional signal transduction of integrin αIIbβ3 through its interactions with the integrin β3 cytoplasmic tail. Specifically, α-actinin-1 can bind to the F727AK FEE ERA R736 sequence within the human integrin β3 cytoplasmic tail, contributing to the formation of focal adhesions and facilitating the linkage between integrins and the cytoskeleton [124,125]. At cell adhesion sites, such as focal adhesions, α-actinin-1 serves as a linker between F-actin and integrins. The ABD of α-actinin-1 can bind to integrins either directly or with the assistance of associated proteins such as talin, vinculin, zyxin, and tensin [85,91]. Consequently, α-actinin-1 is implicated in integrin αIIbβ3-mediated bidirectional signal transduction in platelets [75,126]. Under shear stress conditions, α-actinin dissociates from the β3 integrin tail [127]. Nonetheless, the precise role of α-actinin-1 in integrin αIIbβ3 bidirectional signaling remains inadequately characterized. Investigations utilizing a Chinese hamster ovary (CHO) cell model have demonstrated that the interaction between α-actinin-1 and the integrin β3 cytoplasmic tail contributes to maintaining integrin αIIbβ3 in an inactive state [124,125]. Recent research has indicated that α-actinin acts as a negative regulator, sustaining integrin αIIbβ3 in a low-affinity state [126]. Through coimmunoprecipitation assays, Tadokoro et al. reported that α-actinin is constitutively associated with integrin αIIbβ3 in resting platelets [126]. Upon stimulation of platelets with protease-activated receptor 1-activating peptide (PAR1-AP), α-actinin dissociates from integrin αIIbβ3. Remarkably, α-actinin reassociated with integrin αIIbβ3 20 min after PAR1-AP stimulation. Potential α-actinin binding sites on the human integrin β3 cytoplasmic tail partially overlap with talin binding sites. When associated with integrin αIIbβ3, α-actinin may obstruct talin access to the integrin β3 cytoplasmic tail [124,126]. α-Actinin and talin compete for binding to the integrin β3 cytoplasmic tail [128]. Recent research has indicated that the activation of integrin αIIbβ3 leads to an increase in cytoplasmic Ca2+ levels in platelets, subsequently activating calpain [129]. Activated calpain cleaves talin into head and rod domains [129]. Integrin-binding site 2 (IBS2) within the talin rod can interact with the E726FA KFE EE733 sequence of the human integrin β3 cytoplasmic tail, contributing to the formation of focal adhesions and facilitating the linkage between integrins and the cytoskeleton [130]. A study conducted by Roca-Cusachs et al. using mouse embryonic fibroblasts (which express integrin αvβ3 but not integrin αIIbβ3) demonstrated that α-actinin-1 and talin compete for binding to the integrin β3 cytoplasmic tail during focal adhesion maturation [82]. Considering the structural and functional disparities between integrins αvβ3 and αIIbβ3, the potential competitive interaction between α-actinin-1 and talin rods in the bidirectional signal transduction of integrin αIIbβ3 remains unresolved. Shams et al. demonstrated that α-actinin disrupts integrin αIIbβ3 signaling by inducing a kink in the transmembrane domain of integrin β3 [128]. In the human megakaryoblast cell line CMK, where α-actinin-1 expression was reduced via short hairpin RNA (shRNA) technology, decreased α-actinin levels increased integrin αIIbβ3 activation in response to PAR1-AP [126]. Conversely, the overexpression of wild-type α-actinin inhibited PAR1-AP-induced integrin αIIbβ3 activation [126].
In MKs expressing the human α-actinin-1 Q32K or V105I mutants, the number of proplatelets per MK decreased, although the size of the proplatelets increased [32]. Integrin αIIbβ3 and its bidirectional signaling are crucial for platelet production [46,131]. Mutations leading to constitutively activated integrin αIIbβ3, such as the R995W mutation in the integrin αIIb subunit or the D723H mutation in the integrin β3 subunit, have been associated with thrombocytopenia [132,133]. The activation of integrin αIIbβ3 by IgM autoantibodies leads to a decrease in platelet production [134]. The absence of Rasa3 or filamin A has been shown to result in the upregulation of integrin αIIbβ3 signaling, consequently diminishing platelet production [135,136]. Conversely, the inhibition of several key kinases within the integrin αIIbβ3 signal transduction pathway, specifically through the use of SU6656 (a Src inhibitor) and Y27632 (a Rho-related kinase inhibitor), has been shown to increase proplatelet production [135,137]. Our findings indicate that the inhibition of integrin αIIbβ3 outside-in of the signal transduction pathway using ibrutinib facilitates proplatelet production [46]. Collectively, these studies suggest that α-actinin-1 may play a regulatory role in integrin αIIbβ3 signaling, thereby influencing platelet production.

5.2. Actin

The current understanding of the function or role of α-actinin-1 in the actin filament-based cytoskeleton is not derived from MKs or platelets but rather from various cells, including CHO cells, fibroblasts and HeLa cells, which indicates that α-actinin-1 cross-links actin into bundles. CHO cells were transfected with different α-actinin-1 mutants (Q32K, R46Q, V105I, R197W, E225K, R738W, R752Q, or L395Q mutant) [32,36]; COS-7 cells were transfected with an R46Q mutant [34]; fibroblasts were transfected with individual D22N, R46W, G251R, D666V, T737N, G764S, or E769K mutants [35]; and HeLa cells were transfected with individual Q32K, R46Q, V105I, E225K, R738W, or R752Q mutants [76]. All of these findings showed that the α-actinin-1 mutants caused varying degrees of disorganization of the actin filaments in the mutant-transduced cells. The α-actinin-1 mutants colocalized with less fine, shortened actin filaments. The unbound α-actinin-1 mutants were coarsely distributed within the cytoplasm, and actin–filament organization was deregulated. Consistently, in vitro assays further confirmed that these mutants display increased binding affinity for F-actin and altered actin-binding properties, which aligns with the cytoskeletal disorganization observed in mutant-transfected cells [32,36,76]. However, the aforementioned studies have two key limitations: (1) none of the cell lines used were MK-derived, precluding direct extrapolation to MK or platelet biology, and (2) all tested cells retained endogenous wild-type α-actinin-1 expression, which may mask the true phenotypic effects of the mutants due to potential functional compensation.
In addition to its interaction with actin, α-actinin has been described as a major platform involved in interactions with many cytoskeletal proteins and signaling regulatory proteins. At the site of cell–cell and cell–matrix adhesions, α-actinin interacts with cell surface receptors such as integrin receptors and the N-methyl-D-aspartate (NMDA) receptor. In focal adhesions, α-actinin also binds to zyxin, capZ and vinculin to induce mechanochemical conversion. In muscle, α-actinin interacts with titin and Z-disk proteins, such as z-band alternatingly structured protein (ZASP) and myotilin. In addition, several intracellular molecules, such as the protein kinases PKN and mitogen-activated protein kinase kinase kinase 1 (MEKK1); PDZ domain proteins, such as ZASP/cypher; and zinc-finger proteins, such as ALP, interact with α-actinin, and these interactions contribute to the most important contractile functions in muscle cells [138]. Zyxin, a focal adhesion protein widely expressed in eukaryotes that regulates actin filament-based cytoskeleton remodeling, plays important roles in MK and platelet biology. Zyxin-deficient (Zyx−/−) mice present increased numbers of immature Stage I MKs and reduced numbers of mature Stage II/III MKs [139].

5.3. C-Terminal LIM Domain Protein of 36 kDa (CLP36)

Bauer et al. reported that human CLP36, a PDZ-domain and LIM-domain protein, binds to spectrin-like repeats 2 and 3 within the rod domain of α-actinin-1 and associates with actin filaments and stress fibers in activated platelets and endothelial cells [86]. CLP36 binds to α-actinin-1 in resting platelets, and the CLP36/α-actinin-1 complex is translocated to the newly formed actin filament-based cytoskeleton in activated platelets [86]. This study suggested that by binding to α-actinin-1, CLP36 may direct it to specific actin structures (such as stress fibers) and potentially modulate its function, such as enhancing its actin cross-linking and bundling activities, thereby playing a role in cytoskeletal remodeling during changes in cell shape and migration. The CLP36-α-actinin-1 complex represents a novel functional unit that regulates actin filament-based cytoskeleton dynamics and is likely to contribute to the final crucial steps of platelet generation by MKs.

5.4. Integrins β2 and β1 and Integrin α5

Several integrins, including LFA-1 (integrin αLβ2) and Mac-1 (integrin αMβ2), share a common β2 subunit and are present exclusively on leukocytes [89]. Circulating leukocytes are nonadherent but bind tightly to endothelial cells following the activation of leukocyte integrins. The increased avidity of leukocyte integrins for endothelial ligands is regulated, in part, by interaction of the β2 subunit cytoplasmic tail with the actin filament-based cytoskeleton. The integrin αLβ2 is linked to the actin filament-based cytoskeleton through α-actinin-1 [90]. The association of α-actinin with integrins may stabilize the actin filament-based cytoskeleton and promote firm leukocyte adhesion to and migration across the endothelium [140]. The activation of neutrophils results in an α-actinin-mediated association between integrin β2 and actin filaments [141]. α-Actinin binds to the cytoplasmic domain of integrin αLβ2 with an extended low-intermediate affinity conformation of the large extracellular domain [142]. The affinity of α-actinin for the integrin β2 tail is regulated by a conformational change in the β2 tail, which exposes a cryptic α-actinin binding domain. A positive domain and an inhibitory domain within the β2 tail regulate α-actinin binding. Residues 736–746 of the β2 tail are necessary and sufficient for α-actinin binding; however, residues 748–762 of the β2 tail inhibit the constitutive association of the β2 tail with α-actinin [140]. In contrast, α-actinin is constitutively associated with β1 integrins in fibroblasts [81]. The binding of α-Actinin to the full-length integrin β1 tail was 9.7-fold greater than that to the full-length integrin β2 tail [140]. It has been reported that α-actinin can cooperate with talin to activate integrin α5β1 by restricting cytoplasmic tail movement [128]. Integrin α5 is a member of the integrin protein family. Wang et al. reported that α-actinin-1 interacts with integrin α5 to promote cell proliferation, invasion, and epithelial–mesenchymal transformation in head and neck squamous cell carcinoma [83].
Integrin β2 is not expressed on MKs or platelets. Integrin β1 plays multifaceted roles in MK and platelet biology through its association with various α subunits, tightly regulating core processes, including adhesion, niche migration, maturation, and platelet production. Integrin α5β1 is pivotal for MK adhesion to fibronectin (FN), a key extracellular matrix (ECM) component in the BM microenvironment. This Integrin α5β1-FN interaction directly supports MK expansion and maturation. Ex vivo studies have shown enhanced MK growth when cultured on FN, whereas antibody-mediated inhibition of the α5 subunit abrogates this promegakaryopoietic effect [143]. Pathologically, in primary myelofibrosis (PMF) driven by the JAK2V617F mutation, MKs exhibit upregulated α5β1 expression and activation, leading to abnormally increased adhesion to FNs and uncontrolled MK proliferation; crucially, targeting the α5 subunit with neutralizing antibodies reduces the number of MKs both in vitro and in vivo, highlighting the therapeutic potential of disrupting this β1-dependent axis [144]. In addition to FN adhesion, integrin α5β1 governs MK localization across BM niches: in immature MKs, activated integrin α5β1 mediates retention in the endosteal niche to initiate early maturation [145]. Integrin β1 also modulates how MKs respond to collagen through its association with the α2 subunit to form Integrin α2β1. Specifically, when α2β1 is constitutively activated in MKs, it leads to a ligand-dependent reduction in the amount of α2β1 present on the MK surface. This decrease in surface α2β1 is important because it stops MKs from sticking too early (prematurely) to the collagen-rich environment of the BM. By avoiding this premature adhesion, MKs can move smoothly and unobstructed to the vascular niche—the site where they complete the process of thrombopoiesis (platelet production) properly [146]. Conditional knockout of integrin α2β1 in murine MKs results in a significant reduction in the mean platelet volume (MPV), demonstrating the role of integrin β1 in fine-tuning platelet biogenesis by influencing the timing of MK maturation and the efficiency of proplatelet formation [147]. Integrin α4β1 enhances thrombopoietin-induced megakaryopoiesis [143].

5.5. Phospholipase D (PLD)

PLD regulates actin cytoskeleton-dependent antimicrobial responses of myeloid leukocytes, including oxidant generation and phagocytosis [92]. Although platelet production was not altered, PLD1-deficient MKs displayed abnormal actin rearrangement and highly altered ultrastructures in vivo, with almost no formation of podosomes upon spreading on collagen I in vitro [148]. PLD activity is essential for podosome formation in MKs, macrophages and dendritic cells [148,149]. Studies suggest that α-actinin-1 may interact with PLD1 in fibroblasts [92,150]. After activation by RhoA and Rac1, PLD1 binds to α-actinin-1, thus facilitating the interaction between α-actinin-1 and integrin αLβ2 [151]. In cardiac muscle, PLD2 directly interacts with and is inhibited by α-actinin, a regulatory mechanism that is reversibly overcome by the small GTP-binding protein ADP-ribosylation factor (ARF) [93]. After MK/erythroid progenitors further develop into more mature MKs, phospholipase D signaling is highly expressed [152]. However, the role of phospholipase D in the process of thrombopoiesis remains to be studied.

5.6. Mps One Binder Kinase Activator-like 1 (MOB1)

MOB1 is an important protein in the Hippo pathway [153]. The classical Hippo signaling pathway mainly consists of large tumor kuppressor kinase (LATS)1/2 kinase, mammalian ste20-like kinase (MST)1/2 kinase, the scaffold proteins SAV1 and MOB1 and downstream transcription coactivators (Yes-associated protein (YAP) and transcriptional coactivator with PDZ-binding motif (TAZ)) [153]. The Hippo pathway plays an essential role in regulating MK proliferation, differentiation and platelet biogenesis [154,155]. In hepatocellular carcinoma (HCC) tissues, Chen reported that α-actinin-1 competitively interacts with MOB1 and decreases the phosphorylation of LATS1/YAP to regulate Hippo signaling activity [94]. Lorthongpanich et al. reported that a reduction in the activity of the Hippo core kinase LATS1/2 inhibits platelet production [155]. MOB1 is known to affect tubulin stability [156] and is significantly associated with platelet count [157]. However, whether α-actinin-1 interacts with MOB1 in MKs and platelets is an important but unanswered question.

5.7. LATS6 Guanine–Nucleotide Exchange Factor, Cytohesin-2 (CYTH2)

Cytohesin-2 (CYTH2, also known as ARF nucleotide-binding site opener (ARNO)), an Arf6 guanine-nucleotide exchange factor (GEF), is necessary for the development of granule neurons in the hippocampus [158]. The cytohesin inhibitor SecinH3 significantly enhances dense platelet granule secretion and aggregation [159]. Interestingly, studies conducted by van den Bosch MT et al. demonstrated that cytohesin-2 is a candidate conventional protein kinase C (PKC) substrate in platelets. Following platelet activation, cytohesin-2 is phosphorylated by PKC, leading to the inactivation of Arf6 and facilitating granule secretion [159]. Cytohesin-2 contains amino acids 386–400 (RKK RIS VKK KQE QP) at the C-terminus. α-Actinin-1 interacts with proteins with highly positively charged residues (such as RKK IK and RRF EKE KLK SQ) [160]. Using coimmunoprecipitation, Torii et al. reported that cytohesin-2 interacts with α-actinin-1 and regulates neurite extension in N1E-115 cells [95]. However, it is unclear whether the interactions of α-actinin-1 with cytohesin-2 also occur in MKs and platelets.

5.8. The Exchange Factor for Arf6 (EFA6)

The EFA6 family consists of four isoforms (EFA6A, EFA6B, EFA6C and EFA6D). EFA6 comprises an N-terminal disordered domain, a conserved catalytic Sec7 domain that bears nucleotide exchange activity, a pleckstrin homology (PH) domain responsible for plasma membrane localization and is involved in actin filament-based cytoskeleton rearrangement, and a C-terminal coiled–coil domain for protein–protein interactions [161]. EFA6 has been reported to be upregulated during cortical neuron maturation [162], and the functions of EFA6 are associated with neurologic disorders and human gliomas [163]. Using a two-hybrid screen, Milanini et al. reported that EFA6A could bind to the spectrin domain of α-actinin-1 through its C-terminal domain [96,164]. During lumen formation, EFA6A recruits α-actinin 1 to cortical F-actin structures through direct binding. However, there are currently no studies reporting whether the interaction between EFA6 (or EFA6A) and α-actinin-1 can affect thrombopoiesis.

5.9. Ataxin-2 (Sca2)

Ataxin-2 (human gene symbol ATXN2, protein ATXN2), a polyglutamine repeat protein, is the autosomal dominant neurodegenerative disorder disease protein of spinocerebellar ataxia type 2 (SCA2). Recent research has revealed that ataxin-2 proteins play important roles in regulating global mRNA stability and translation [165,166]. Ataxin-2 directly binds to more than 4000 transcripts, with a preference for binding to their 3′-untranslated region [167]. Genome-wide association studies revealed that single-nucleotide polymorphisms (SNPs) in the ATXN2 locus were associated with an increased risk for thrombotic antiphospholipid syndrome [168]. A recent study revealed that ataxin-2 controls the onset of terminal differentiation in megakaryopoiesis, modulates the MK transcriptome and proteome, and affects the expression of platelet surface proteins [169]. Platelets from ataxin-2 knockout mice presented increased expression of cluster of differentiation 31 (CD31) and impaired αIIbβ3 integrin-mediated platelet aggregation with phorbol myristate acetate (PMA) or with Aggretin A stimulation. In vitro glutathione S-transferase (GST)-tag pull-down experiments revealed that the CH domain at the N-terminus of α-actinin-1 binds to the N-terminus of ataxin-2 [87]. The interaction of ataxin-2 with α-actinin-1 might regulate actin-α-actinin-1 interactions since some ABD motifs of α-actinin-1 have been reported to function as signaling scaffolds and as microtubule-binding sites [170,171].
ATXN2 is highly expressed in early megakaryoblasts and is downregulated during terminal MK maturation. It associates with DEAD-box helicase 6 (DDX6) and poly(A)-binding protein (PABP), suggesting that it plays a role in the repression of mRNA translation. Depletion of ATXN2 in megakaryocytic cells (e.g., MEG-01) leads to the deregulation of mRNAs and proteins involved in platelet function and hemostasis pathways, such as integrin β3, F2R, and VAV1. In vivo, Atxn2−/− mice presented a reduction in stage IV megakaryocytic cells and impaired platelet aggregation, specifically in response to αIIbβ3 integrin-mediated activation, despite normal platelet counts and bleeding. Thus, ATXN2 appears to fine-tune gene expression during early megakaryopoiesis, affecting downstream platelet reactivity [169,172]. However, the functional consequences of the interaction of ataxin-2 with α-actinin-1 remain to be elucidated.

5.10. L-Type Ca2+ Channel CaV1.2

The L-type Ca2+ channel CaV1.2 plays essential roles in cardiac contraction, gene expression and neuronal activity [173]. Binding of α-actinin-1 to the IQ motif of CaV1.2 supports CaV1.2 surface localization and postsynaptic targeting in neurons. Turner et al. reported that CaV1.2 anchoring at defined surface regions is mediated by α-actinin-1 and simultaneously increases the probability of CaV1.2 opening [97]. The EF3/EF4 domain of α-actinin-1 binds to the CaV1.2 IQ motif [97]. The EF hands of α-actinin-1 are unable to bind to Ca2+ under physiological conditions [174]. Therefore, the EF hands of α-actinin-1 binding to CaV1.2 are in the Ca2+-free state. In addition, α-actinin-2 binds to cardiac Kv1.5 channels and regulates current density and channel localization in HEK cells [175]. The primary function of CaV1.2 is well known in excitable cells, including cardiomyocytes and neurons [176]. In contrast, its role in MKs and platelets is less defined. MKs and platelets principally utilize distinct mechanisms for calcium entry [177,178,179].

5.11. Transient Receptor Potential (TRP) Polycystin 2 and 3

Polycystin 2 is a transient receptor potential (TRP)-type, Ca2+-permeable nonselective cation channel. Using a yeast two-hybrid approach, Li et al. discovered that both the N- and C-terminal domains of polycystin 2 (PC2) associate with α-actinins [98]. The PC2-α-actinin interaction leads to a substantial increase in the channel activity of polycystin-2, which is important for cell adhesion, cytoskeleton organization, proliferation and migration [98]. The transient receptor potential polycystin 3 (TRPP3)-α-actinin interaction was confirmed via yeast two-hybrid, coimmunoprecipitation and in vitro binding assays [99]. Furthermore, α-actinin not only regulates the channel function of polycystin 3 but also attaches TRPP3 to the cytoskeleton [99]. However, the direct functional roles of TRP polycystin 2 and 3 and NMDA receptors in MKs and platelets are not well established.

5.12. N-Methyl-D-aspartate (NMDA) Receptors

The NMDA receptor is a tetramer that consists of two obligatory NR1 subunits and two regulatory subunits [180]. The NMDA receptor is responsible for mediating Ca2+ influx into cells. Specifically, after Ca2+ enters the cell, it binds to the Ca2+-binding protein calmodulin to form a Ca2+/CaM complex. This complex then interacts with the NMDA receptor, and through this interaction, it further activates Ca2+/calmodulin-dependent kinase II (CaMKII) [88]. Residues 845--863 in the membrane-proximal C0 region of the NR1 subunit interact with several postsynaptic proteins, including α-actinin, CaMKII and CaM. Recent studies have shown that CaM is sufficient to displace α-actinin, which in turn promotes CaMKII binding under Ca2+-saturated conditions. However, CaM does not compete with α-actinin for NR1 C0 binding under Ca2+-free conditions [88]. NMDA receptors have emerged as pivotal regulators of MK and platelet function, directly influencing the core processes of thrombopoiesis, including MK maturation, proplatelet formation, and platelet activation. In MKs, functional NMDA receptors (composed of obligate GluN1 (encoded by Grin1), NR2A, and NR2D subunits) are essential for terminal differentiation and maturation [181,182]. Antagonizing these receptors with MK-801 profoundly inhibits the maturation of CD34+ progenitor-derived MKs, reducing the expression of MK-specific markers (CD41, CD61, and CD42a) and disrupting the formation of α-granules and the demarcation membrane system (DMS) [182]. This regulatory role was further validated by in vivo studies using MK/platelet-specific Grin1 knockout (PF4-Grin1−/−) mice [183]. Grin1 knockout MKs presented reduced colony formation, impaired proplatelet formation, and disrupted F-actin and α-tubulin reorganization. Transcriptomic analysis further revealed that NMDA receptor signaling influences ECM remodeling by regulating the expression of ECM components [183]. Importantly, NMDA receptor expression in MKs is maintained even in c-Mpl knockout mice (deficient in thrombopoietin (TPO) signaling), indicating that the NMDAR-dependent regulation of MK function operates independently of the canonical TPO/c-Mpl pathway [182].

5.13. Metabotropic Glutamate Receptor Type 5b (mGlu5b) Receptor

α-Actinin-1 was identified as a binding partner for the C-terminal domain of the mGlu5b receptor via a yeast two-hybrid screen [100]. The interaction of α-actinin-1 with the mGlu5b receptor regulates mGlu5b receptor expression on the cell surface. In addition, the interaction between α-actinin-1 and the mGlu5b receptor affects the receptor-mediated activation of the mitogen-activated protein kinase (MAPK) pathway [100]. However, whether the mGlu5b receptor is expressed and its functional role in MKs and platelets have not yet been determined.

5.14. Alström Syndrome Protein 1 (ALMS1)

The Alström syndrome protein ALMS1 was reported to interact with α-actinin, a component of the endosome recycling pathway [84]. The spectrin repeats and EF hands of α-actinin are important for its interaction with ALMS1 [84]. The interaction of α-actinin with ALMS1 is involved in the TGF-β signaling pathway [184]. However, whether ALMS1 is expressed in MKs and, if so, its role and interaction with α-actinin remain to be investigated.

5.15. Mitogen-Activated Protein Kinase Kinase Kinase 1 (MEKK1)

Direct interaction between mitogen-activated protein kinase (MAPK)/ERK kinase 1 (MEKK1) and α-actinin has been shown by residues 221--559 of MEKK1 binding to purified α-actinin in vitro [101]. MEKK1 and a-actinin form a complex in vitro and coimmunoprecipitate from 293T cell lysates [101]. Endogenous MEKK1 colocalizes with α-actinin along actin stress fibers and at focal adhesions in Madin–Darby canine kidney (MDCK) cells [101]. However, the specific role of MEKK1 in MKs and platelets has not been extensively studied.

5.16. Oroxylin A (OA)

Oroxylin A is a flavonoid extracted from the traditional Chinese medicine Scutellaria baicalensis Georgi. Oroxylin A has been reported to have antithrombotic, anti-inflammatory, proapoptotic and antitumor activities [102,185]. Oroxylin A can specifically bind to α-actinin-1 [102]. These interactions significantly prevent the activation of cancer-associated fibroblasts and restrain breast cancer metastasis [102].

6. Future Directions

Recent studies have revealed that mutations in the ACTN1 gene are associated with inherited thrombocytopenia, but little is known about the exact role of α-actinin-1 in thrombocytopoiesis and its underlying mechanism. Many gaps remain to be filled in research on the mechanism of platelet production by interactions between α-actinin-1 and its partners. For example, mutations in α-actinin-1 affect the expression level of its partners during MK maturation and platelet production. Mutations in α-actinin-1 can cause thrombocytopenia, but whether mutations in α-actinin-1 affect its protein–protein interactions remains unknown. Homozygous ACTN1−/− mice are not viable [77]. MK/platelet lineage-specific α-actinin-1 mutant knock-in should be used to investigate MK maturation and thrombocytopoiesis. To investigate the molecular mechanism underlying the role of α-actinin-1 in thrombocytopenia, the expression and localization of α-actinin-1, actin, integrin αIIbβ3 and other partners should also be examined in MKs. We hope to further elucidate the underlying mechanism of α-actinin-1 in thrombocytopoiesis and integrin αIIbβ3 signaling.

Author Contributions

Conceptualization, L.W.; writing—original draft preparation, L.W.; writing—review and editing, Z.S. and Y.Z.; supervision, X.H.; project administration, J.H.; funding acquisition, general review, and final revision of the manuscript, J.H. All authors have read and agreed to the published version of the manuscript.

Funding

This research was funded by the National Natural Science Foundations of China (82070118) and the Science Program of the Health Commission of Jiangxi Province (202210433).

Institutional Review Board Statement

Not applicable.

Informed Consent Statement

Not applicable.

Data Availability Statement

No new data were created or analyzed in this study. Data sharing is not applicable to this article.

Conflicts of Interest

The authors declare no conflicts of interest.

Abbreviations

The following abbreviations are used in this manuscript:
ABDActin-binding domain
ABSsActin-binding sites
ADPAdenosine diphosphate
ALMS1Alström syndrome protein 1
ARFADP-ribosylation factor
ARNOARF nucleotide-binding site opener
BMBone marrow
CaMCalmodulin-like
CaMDCalmodulin-like domain
CaMKIICa2+/calmodulin-dependent kinase II
CDCluster of differentiation
CHCalponin homology
CMTPCongenital macrothrombocytopenia
CHOChinese hamster ovary
CYTH2Cytohesin-2
DDX6DEAD-box helicase 6
DMSDemarcation membrane system
ECMExtracellular matrix
EFE-helix and F-helix
EFA6Exchange factor for Arf6
FGF-4Fibroblast growth factor-4
FNFibronectin
GEFGuanine-nucleotide exchange factor
GPGlycoprotein
HCCHepatocellular carcinoma
HSCsHematopoietic stem cells
IBS2Integrin-binding site 2
ILKIntegrin-linked kinase
ITAMImmunoreceptor tyrosine-based activation motif
MAPKMitogen-activated protein kinase
MDCKMadin–Darby canine kidney
MEKK1Mitogen-activated protein kinase kinase kinase 1
mGlu5bMetabotropic glutamate receptor type 5b
MKMegakaryocyte
MOB1Mps one binder kinase activator-like 1
MPVMean platelet volume
MSTMammalian ste20-like kinase
NMDAN-methyl-D-aspartate
LATSLarge tumor suppressor kinase
OAOroxylin A
PABPPoly(A)-binding protein
PAR1-APProtease-activated receptor 1-activating peptide
PC2Polycystin 2
PF4Platelet factor 4
PHPleckstrin homology
PKNProtein kinase N
PKCProtein kinase C
PLDPhospholipase D
PMAPhorbol myristate acetate
PMFPrimary myelofibrosis
p-TEFbPositive transcription elongation factor b
SCA2Spinocerebellar ataxia type 2
SDF-1αStromal cell-derived factor 1 α
SFKsSrc family kinases
shRNAShort hairpin RNA
SLRSpectrin-like repeat
SNPsSingle-nucleotide polymorphisms
SRSpectrin repeat
SykSpleen tyrosine kinase
TPOThrombopoietin
TRPTransient receptor potential
TRPP3Transient receptor potential polycystin 3
TXA2Thromboxane A2
VPS33BVacuolar protein sorting-associated protein 33B
YAPYes-associated protein
ZASPZ-band alternatingly structured protein
TAZTranscriptional coactivator with PDZ-binding motif

References

  1. Almazni, I.; Stapley, R.; Morgan, N.V. Inherited thrombocytopenia: Update on genes and genetic variants which may be associated with bleeding. Front. Cardiovasc. Med. 2019, 6, 80. [Google Scholar] [CrossRef]
  2. Marin-Quilez, A.; Sanchez-Fuentes, A.; Zamora-Canovas, A.; Gomez-Gonzalez, P.L.; Diaz-Ajenjo, L.; Benito, R.; Rodriguez-Alen, A.; Sevivas, T.; Murciano, T.; Murillo, L.; et al. Insights into the clinical, platelet and genetic landscape of inherited thrombocytopenia with malignancy risk. Br. J. Haematol. 2025. [Google Scholar] [CrossRef]
  3. Sadaf, A.; Ware, R.E. Microscope diagnosis of MYH9-related thrombocytopenia. Blood 2021, 138, 1000. [Google Scholar] [CrossRef]
  4. Vassallo, P.; Westbury, S.K.; Mumford, A.D. FLNA variants associated with disorders of platelet number or function. Platelets 2020, 31, 1097–1100. [Google Scholar] [CrossRef]
  5. Hou, Y.; Shao, L.; Zhou, H.; Liu, Y.; Fisk, D.G.; Spiteri, E.; Zehnder, J.L.; Peng, J.; Zhang, B.M.; Hou, M. Identification of a pathogenic TUBB1 variant in a Chinese family with congenital macrothrombocytopenia through whole genome sequencing. Platelets 2021, 32, 1108–1112. [Google Scholar] [CrossRef]
  6. Jiang, J.; Zhou, J.; Wei, M.; Singh, S.; Nikuze, L.; Huang, L.; Li, Y.; Jiang, J.; Wei, H. Clinical and molecular characteristics of Wiskott-Aldrich Syndrome in five unrelated Chinese families. Scand. J. Immunol. 2022, 95, e13115. [Google Scholar] [CrossRef]
  7. Karki, N.R.; Ajebo, G.; Savage, N.; Kutlar, A. DIAPH1 mutation as a novel cause of autosomal dominant macrothrombocytopenia and hearing Loss. Acta Haematol. 2021, 144, 91–94. [Google Scholar] [CrossRef]
  8. Marin-Quilez, A.; Vuelta, E.; Diaz-Ajenjo, L.; Fernandez-Infante, C.; Garcia-Tunon, I.; Benito, R.; Palma-Barqueros, V.; Hernandez-Rivas, J.M.; Gonzalez-Porras, J.R.; Rivera, J.; et al. A novel nonsense variant in TPM4 caused dominant macrothrombocytopenia, mild bleeding tendency and disrupted cytoskeleton remodeling. J. Thromb. Haemost. 2022, 20, 1248–1255. [Google Scholar] [CrossRef]
  9. O’Sullivan, L.R.; Cahill, M.R.; Young, P.W. The importance of α-actinin proteins in platelet formation and function, and their causative role in congenital macrothrombocytopenia. Int. J. Mol. Sci. 2021, 22, 9363. [Google Scholar] [CrossRef]
  10. Stritt, S.; Nurden, P.; Favier, R.; Favier, M.; Ferioli, S.; Gotru, S.K.; van Eeuwijk, J.M.; Schulze, H.; Nurden, A.T.; Lambert, M.P.; et al. Defects in TRPM7 channel function deregulate thrombopoiesis through altered cellular Mg2+ homeostasis and cytoskeletal architecture. Nat. Commun. 2016, 7, 11097. [Google Scholar] [CrossRef]
  11. Leinoe, E.; Brons, N.; Rasmussen, A.O.; Gabrielaite, M.; Zaninetti, C.; Palankar, R.; Zetterberg, E.; Rosthoj, S.; Ostrowski, S.R.; Rossing, M. The Copenhagen founder variant GP1BA c.58T>G is the most frequent cause of inherited thrombocytopenia in Denmark. J. Thromb. Haemost. 2021, 19, 2884–2892. [Google Scholar] [CrossRef]
  12. Sivapalaratnam, S.; Westbury, S.K.; Stephens, J.C.; Greene, D.; Downes, K.; Kelly, A.M.; Lentaigne, C.; Astle, W.J.; Huizinga, E.G.; Nurden, P.; et al. Rare variants in GP1BB are responsible for autosomal dominant macrothrombocytopenia. Blood 2017, 129, 520–524. [Google Scholar] [CrossRef]
  13. Lin, Q.; Zhou, R.; Meng, P.; Wu, L.; Yang, L.; Liu, W.; Wu, J.; Cheng, Y.; Shi, L.; Zhang, Y. Establishment of a Bernard-Soulier syndrome model in zebrafish. Haematologica 2022, 107, 1655–1668. [Google Scholar] [CrossRef]
  14. Morais, S.; Oliveira, J.; Lau, C.; Pereira, M.; Goncalves, M.; Monteiro, C.; Goncalves, A.R.; Matos, R.; Sampaio, M.; Cruz, E.; et al. αIIbβ3 variants in ten families with autosomal dominant macrothrombocytopenia: Expanding the mutational and clinical spectrum. PLoS ONE 2020, 15, e0235136. [Google Scholar] [CrossRef]
  15. Al Rimon, R.; Sayem, M.; Alam, S.; Al Saba, A.; Sanyal, M.; Amin, M.R.; Kabir, A.; Chakraborty, S.; Nabi, A. The polymorphic landscape analysis of GATA1 exons uncovered the genetic variants associated with higher thrombocytopenia in dengue patients. PLoS Negl. Trop. Dis. 2022, 16, e0010537. [Google Scholar] [CrossRef]
  16. Al-Abboh, H.; Zahra, A.; Adekile, A. A novel MECOM variant associated with congenital amegakaryocytic thrombocytopenia and radioulnar synostosis. Pediatr. Blood Cancer 2022, 69, e29761. [Google Scholar] [CrossRef]
  17. Vo, K.K.; Jarocha, D.J.; Lyde, R.B.; Hayes, V.; Thom, C.S.; Sullivan, S.K.; French, D.L.; Poncz, M. FLI1 level during megakaryopoiesis affects thrombopoiesis and platelet biology. Blood 2017, 129, 3486–3494. [Google Scholar] [CrossRef]
  18. Borst, S.; Nations, C.C.; Klein, J.G.; Pavani, G.; Maguire, J.A.; Camire, R.M.; Drazer, M.W.; Godley, L.A.; French, D.L.; Poncz, M.; et al. Study of inherited thrombocytopenia resulting from mutations in ETV6 or RUNX1 using a human pluripotent stem cell model. Stem Cell Rep. 2021, 16, 1458–1467. [Google Scholar] [CrossRef]
  19. Horvat-Switzer, R.D.; Thompson, A.A. HOXA11 mutation in amegakaryocytic thrombocytopenia with radio-ulnar synostosis syndrome inhibits megakaryocytic differentiation in vitro. Blood Cells Mol. Dis. 2006, 37, 55–63. [Google Scholar] [CrossRef]
  20. Faleschini, M.; Ammeti, D.; Papa, N.; Alfano, C.; Bottega, R.; Fontana, G.; Capaci, V.; Zanchetta, M.E.; Pozzani, F.; Montanari, F.; et al. ETV6-related thrombocytopenia: Dominant negative effect of mutations as common pathogenic mechanism. Haematologica 2022, 107, 2249–2254. [Google Scholar] [CrossRef]
  21. Faleschini, M.; Papa, N.; Morel-Kopp, M.C.; Marconi, C.; Giangregorio, T.; Melazzini, F.; Bozzi, V.; Seri, M.; Noris, P.; Pecci, A.; et al. Dysregulation of oncogenic factors by GFI1B p32: Investigation of a novel GFI1B germline mutation. Haematologica 2022, 107, 260–267. [Google Scholar] [CrossRef]
  22. Riley, R.; Khan, A.; Pai, S.; Warmke, L.; Winkler, M.; Gunning, W. A case of chronic thrombocytopenia in a 17-year-old female. Lab. Med. 2019, 50, 406–420. [Google Scholar] [CrossRef]
  23. Stapley, R.J.; Pisareva, V.P.; Pisarev, A.V.; Morgan, N.V. SLFN14 gene mutations associated with bleeding. Platelets 2020, 31, 407–410. [Google Scholar] [CrossRef]
  24. Cornish, N.; Aungraheeta, M.R.; FitzGibbon, L.; Burley, K.; Alibhai, D.; Collins, J.; Greene, D.; Downes, K.; BioResource, N.; Westbury, S.K.; et al. Monoallelic loss-of-function THPO variants cause heritable thrombocytopenia. Blood Adv. 2020, 4, 920–924. [Google Scholar] [CrossRef]
  25. Yang, L.; Wu, L.; Meng, P.; Zhang, X.; Zhao, D.; Lin, Q.; Zhang, Y. Generation of a thrombopoietin-deficient thrombocytopenia model in zebrafish. J. Thromb. Haemost. 2022, 20, 1900–1909. [Google Scholar] [CrossRef]
  26. Levin, C.; Koren, A.; Pretorius, E.; Rosenberg, N.; Shenkman, B.; Hauschner, H.; Zalman, L.; Khayat, M.; Salama, I.; Elpeleg, O.; et al. Deleterious mutation in the FYB gene is associated with congenital autosomal recessive small-platelet thrombocytopenia. J. Thromb. Haemost. 2015, 13, 1285–1292. [Google Scholar] [CrossRef]
  27. Marklin, M.; Tandler, C.; Kopp, H.G.; Hoehn, K.L.; Quintanilla-Martinez, L.; Borst, O.; Muller, M.R.; Saur, S.J. C-Cbl regulates c-MPL receptor trafficking and its internalization. J. Cell. Mol. Med. 2020, 24, 12491–12503. [Google Scholar] [CrossRef]
  28. Palma-Barqueros, V.; Revilla, N.; Zaninetti, C.; Galera, A.M.; Sanchez-Fuentes, A.; Zamora-Canovas, A.; Bohdan, N.; Padilla, J.; Marin-Quilez, A.; Rodriguez-Alen, A.; et al. Src-related thrombocytopenia: A fine line between a megakaryocyte dysfunction and an immune-mediated disease. Blood Adv. 2022, 6, 5244–5255. [Google Scholar] [CrossRef]
  29. Boussion, S.; Escande, F.; Jourdain, A.S.; Smol, T.; Brunelle, P.; Duhamel, C.; Alembik, Y.; Attie-Bitach, T.; Baujat, G.; Bazin, A.; et al. TAR syndrome: Clinical and molecular characterization of a cohort of 26 patients and description of novel noncoding variants of RBM8A. Hum. Mutat. 2020, 41, 1220–1225. [Google Scholar] [CrossRef]
  30. Sullivan, M.J.; Palmer, E.L.; Botero, J.P. ANKRD26-related thrombocytopenia and predisposition to myeloid neoplasms. Curr. Hematol. Malig. Rep. 2022, 17, 105–112. [Google Scholar] [CrossRef]
  31. Sun, W.; Zhang, T.; Zhang, X.; Wang, J.; Chen, Y.; Long, Y.; Zhang, G.; Wang, Y.; Chen, Y.; Fang, T.; et al. Compound heterozygous mutations in ABCG5 or ABCG8 causing Chinese familial Sitosterolemia. J. Gene Med. 2020, 22, e3185. [Google Scholar] [CrossRef]
  32. Kunishima, S.; Okuno, Y.; Yoshida, K.; Shiraishi, Y.; Sanada, M.; Muramatsu, H.; Chiba, K.; Tanaka, H.; Miyazaki, K.; Sakai, M.; et al. ACTN1 mutations cause congenital macrothrombocytopenia. Am. J. Hum. Genet. 2013, 92, 431–438. [Google Scholar] [CrossRef]
  33. O’Sullivan, L.R.; Ajaykumar, A.P.; Dembicka, K.M.; Murphy, A.; Grennan, E.P.; Young, P.W. Investigation of calmodulin-like and rod domain mutations suggests common molecular mechanism for α-actinin-1-linked congenital macrothrombocytopenia. FEBS Lett. 2020, 594, 161–174. [Google Scholar] [CrossRef]
  34. Gueguen, P.; Rouault, K.; Chen, J.M.; Raguenes, O.; Fichou, Y.; Hardy, E.; Gobin, E.; Pan-Petesch, B.; Kerbiriou, M.; Trouve, P.; et al. A missense mutation in the α-actinin 1 gene (ACTN1) is the cause of autosomal dominant macrothrombocytopenia in a large French family. PLoS ONE 2013, 8, e74728. [Google Scholar] [CrossRef]
  35. Bottega, R.; Marconi, C.; Faleschini, M.; Baj, G.; Cagioni, C.; Pecci, A.; Pippucci, T.; Ramenghi, U.; Pardini, S.; Ngu, L.; et al. ACTN1-related thrombocytopenia: Identification of novel families for phenotypic characterization. Blood 2015, 125, 869–872. [Google Scholar] [CrossRef]
  36. Yasutomi, M.; Kunishima, S.; Okazaki, S.; Tanizawa, A.; Tsuchida, S.; Ohshima, Y. ACTN1 rod domain mutation associated with congenital macrothrombocytopenia. Ann. Hematol. 2016, 95, 141–144. [Google Scholar] [CrossRef]
  37. Luo, F.M.; Fan, L.L.; Sheng, Y.; Dong, Y.; Liu, L. Case report: Exome sequencing identified a novel frameshift mutation of α-actin 1 in a chinese family with macrothrombocytopenia and mild bleeding. Front. Pediatr. 2021, 9, 679279. [Google Scholar] [CrossRef]
  38. Vincenot, A.; Saultier, P.; Kunishima, S.; Poggi, M.; Hurtaud-Roux, M.F.; Roussel, A.; Actn Study, C.; Schlegel, N.; Alessi, M.C. Novel ACTN1 variants in cases of thrombocytopenia. Hum. Mutat. 2019, 40, 2258–2269. [Google Scholar] [CrossRef]
  39. Zanchetta, M.E.; Barozzi, S.; Isidori, F.; Marconi, C.; Farinasso, L.; Bottega, R.; Savoia, A.; Pecci, A.; Faleschini, M. ACTN1-related thrombocytopenia: Homozygosity for an ACTN1 variant results in a more severe phenotype. Br. J. Haematol. 2024, 204, 2453–2457. [Google Scholar] [CrossRef]
  40. Huang, J.; Li, X.; Shi, X.; Zhu, M.; Wang, J.; Huang, S.; Huang, X.; Wang, H.; Li, L.; Deng, H.; et al. Platelet integrin αIIbβ3: Signal transduction, regulation, and its therapeutic targeting. J. Hematol. Oncol. 2019, 12, 26. [Google Scholar] [CrossRef]
  41. Bhatlekar, S.; Manne, B.K.; Basak, I.; Edelstein, L.C.; Tugolukova, E.; Stoller, M.L.; Cody, M.J.; Morley, S.C.; Nagalla, S.; Weyrich, A.S.; et al. miR-125a-5p regulates megakaryocyte proplatelet formation via the actin-bundling protein L-plastin. Blood 2020, 136, 1760–1772. [Google Scholar] [CrossRef] [PubMed]
  42. Bem, D.; Smith, H.; Banushi, B.; Burden, J.J.; White, I.J.; Hanley, J.; Jeremiah, N.; Rieux-Laucat, F.; Bettels, R.; Ariceta, G.; et al. VPS33B regulates protein sorting into and maturation of α-granule progenitor organelles in mouse megakaryocytes. Blood 2015, 126, 133–143. [Google Scholar] [CrossRef]
  43. Psaila, B.; Mead, A.J. Single-cell approaches reveal novel cellular pathways for megakaryocyte and erythroid differentiation. Blood 2019, 133, 1427–1435. [Google Scholar] [CrossRef]
  44. Rodriguez-Fraticelli, A.E.; Wolock, S.L.; Weinreb, C.S.; Panero, R.; Patel, S.H.; Jankovic, M.; Sun, J.; Calogero, R.A.; Klein, A.M.; Camargo, F.D. Clonal analysis of lineage fate in native haematopoiesis. Nature 2018, 553, 212–216. [Google Scholar] [CrossRef]
  45. Wang, H.; He, J.; Xu, C.; Chen, X.; Yang, H.; Shi, S.; Liu, C.; Zeng, Y.; Wu, D.; Bai, Z.; et al. Decoding human megakaryocyte development. Cell Stem Cell 2021, 28, 535–549 e538. [Google Scholar] [CrossRef] [PubMed]
  46. Huang, J.; Huang, S.; Ma, Z.; Lin, X.; Li, X.; Huang, X.; Wang, J.; Ye, W.; Li, Y.; He, D.; et al. Ibrutinib suppresses early megakaryopoiesis but enhances proplatelet formation. Thromb. Haemost. 2021, 121, 192–205. [Google Scholar] [CrossRef]
  47. Lefrancais, E.; Ortiz-Munoz, G.; Caudrillier, A.; Mallavia, B.; Liu, F.; Sayah, D.M.; Thornton, E.E.; Headley, M.B.; David, T.; Coughlin, S.R.; et al. The lung is a site of platelet biogenesis and a reservoir for haematopoietic progenitors. Nature 2017, 544, 105–109. [Google Scholar] [CrossRef]
  48. Suraneni, P.K.; Corey, S.J.; Hession, M.J.; Ishaq, R.; Awomolo, A.; Hasan, S.; Shah, C.; Liu, H.; Wickrema, A.; Debili, N.; et al. Dynamins 2 and 3 control the migration of human megakaryocytes by regulating CXCR4 surface expression and ITGB1 activity. Blood Adv. 2018, 2, 3540–3552. [Google Scholar] [CrossRef]
  49. Lefrancais, E.; Looney, M.R. Platelet biogenesis in the lung circulation. Physiology 2019, 34, 392–401. [Google Scholar] [CrossRef]
  50. Mbiandjeu, S.; Balduini, A.; Malara, A. Megakaryocyte cytoskeletal proteins in platelet biogenesis and diseases. Thromb. Haemost. 2022, 122, 666–678. [Google Scholar] [CrossRef] [PubMed]
  51. Stritt, S.; Beck, S.; Becker, I.C.; Vogtle, T.; Hakala, M.; Heinze, K.G.; Du, X.; Bender, M.; Braun, A.; Lappalainen, P.; et al. Twinfilin 2a regulates platelet reactivity and turnover in mice. Blood 2017, 130, 1746–1756. [Google Scholar] [CrossRef]
  52. Bender, M.; Eckly, A.; Hartwig, J.H.; Elvers, M.; Pleines, I.; Gupta, S.; Krohne, G.; Jeanclos, E.; Gohla, A.; Gurniak, C.; et al. ADF/n-cofilin-dependent actin turnover determines platelet formation and sizing. Blood 2010, 116, 1767–1775. [Google Scholar] [CrossRef]
  53. Rosa, J.P.; Raslova, H.; Bryckaert, M. Filamin A: Key actor in platelet biology. Blood 2019, 134, 1279–1288. [Google Scholar] [CrossRef]
  54. Fritz, D.I.; Ding, Y.; Merrill-Skoloff, G.; Flaumenhaft, R.; Hanada, T.; Chishti, A.H. Dematin regulates calcium mobilization, thrombosis, and early Akt activation in platelets. Mol. Cell. Biol. 2023, 43, 283–299. [Google Scholar] [CrossRef]
  55. Pal, K.; Nowak, R.; Billington, N.; Liu, R.; Ghosh, A.; Sellers, J.R.; Fowler, V.M. Megakaryocyte migration defects due to nonmuscle myosin IIA mutations underlie thrombocytopenia in MYH9-related disease. Blood 2020, 135, 1887–1898. [Google Scholar] [CrossRef]
  56. Englert, M.; Aurbach, K.; Becker, I.C.; Gerber, A.; Heib, T.; Wackerbarth, L.M.; Kusch, C.; Mott, K.; Araujo, G.H.M.; Baig, A.A.; et al. Impaired microtubule dynamics contribute to microthrombocytopenia in RhoB-deficient mice. Blood Adv. 2022, 6, 5184–5197. [Google Scholar] [CrossRef]
  57. Ghalloussi, D.; Dhenge, A.; Bergmeier, W. New insights into cytoskeletal remodeling during platelet production. J. Thromb. Haemost. 2019, 17, 1430–1439. [Google Scholar] [CrossRef]
  58. Leon, C.; Eckly, A.; Hechler, B.; Aleil, B.; Freund, M.; Ravanat, C.; Jourdain, M.; Nonne, C.; Weber, J.; Tiedt, R.; et al. Megakaryocyte-restricted MYH9 inactivation dramatically affects hemostasis while preserving platelet aggregation and secretion. Blood 2007, 110, 3183–3191. [Google Scholar] [CrossRef] [PubMed]
  59. Chen, Z.; Naveiras, O.; Balduini, A.; Mammoto, A.; Conti, M.A.; Adelstein, R.S.; Ingber, D.; Daley, G.Q.; Shivdasani, R.A. The May-Hegglin anomaly gene MYH9 is a negative regulator of platelet biogenesis modulated by the Rho-ROCK pathway. Blood 2007, 110, 171–179. [Google Scholar] [CrossRef] [PubMed]
  60. Nurden, P.; Debili, N.; Coupry, I.; Bryckaert, M.; Youlyouz-Marfak, I.; Sole, G.; Pons, A.C.; Berrou, E.; Adam, F.; Kauskot, A.; et al. Thrombocytopenia resulting from mutations in filamin A can be expressed as an isolated syndrome. Blood 2011, 118, 5928–5937. [Google Scholar] [CrossRef] [PubMed]
  61. Kunishima, S.; Nishimura, S.; Suzuki, H.; Imaizumi, M.; Saito, H. TUBB1 mutation disrupting microtubule assembly impairs proplatelet formation and results in congenital macrothrombocytopenia. Eur. J. Haematol. 2014, 92, 276–282. [Google Scholar] [CrossRef]
  62. Ingrungruanglert, P.; Amarinthnukrowh, P.; Rungsiwiwut, R.; Maneesri-le Grand, S.; Sosothikul, D.; Suphapeetiporn, K.; Israsena, N.; Shotelersuk, V. Wiskott-Aldrich syndrome iPS cells produce megakaryocytes with defects in cytoskeletal rearrangement and proplatelet formation. Thromb. Haemost. 2015, 113, 792–805. [Google Scholar] [CrossRef] [PubMed]
  63. Stritt, S.; Nurden, P.; Turro, E.; Greene, D.; Jansen, S.B.; Westbury, S.K.; Petersen, R.; Astle, W.J.; Marlin, S.; Bariana, T.K.; et al. A gain-of-function variant in DIAPH1 causes dominant macrothrombocytopenia and hearing loss. Blood 2016, 127, 2903–2914. [Google Scholar] [CrossRef]
  64. Pleines, I.; Woods, J.; Chappaz, S.; Kew, V.; Foad, N.; Ballester-Beltran, J.; Aurbach, K.; Lincetto, C.; Lane, R.M.; Schevzov, G.; et al. Mutations in tropomyosin 4 underlie a rare form of human macrothrombocytopenia. J. Clin. Investig. 2017, 127, 814–829. [Google Scholar] [CrossRef]
  65. Raslova, H.; Kauffmann, A.; Sekkai, D.; Ripoche, H.; Larbret, F.; Robert, T.; Tronik Le Roux, D.; Kroemer, G.; Debili, N.; Dessen, P.; et al. Interrelation between polyploidization and megakaryocyte differentiation: A gene profiling approach. Blood 2007, 109, 3225–3234. [Google Scholar] [CrossRef]
  66. Wu, J.Q.; Bahler, J.; Pringle, J.R. Roles of a fimbrin and an α-actinin-like protein in fission yeast cell polarization and cytokinesis. Mol. Biol. Cell 2001, 12, 1061–1077. [Google Scholar] [CrossRef] [PubMed]
  67. Fujiwara, K.; Porter, M.E.; Pollard, T.D. α-actinin localization in the cleavage furrow during cytokinesis. J. Cell Biol. 1978, 79, 268–275. [Google Scholar] [CrossRef] [PubMed]
  68. Elagib, K.E.; Rubinstein, J.D.; Delehanty, L.L.; Ngoh, V.S.; Greer, P.A.; Li, S.; Lee, J.K.; Li, Z.; Orkin, S.H.; Mihaylov, I.S.; et al. Calpain 2 activation of P-TEFb drives megakaryocyte morphogenesis and is disrupted by leukemogenic GATA1 mutation. Dev. Cell 2013, 27, 607–620. [Google Scholar] [CrossRef]
  69. Mukhina, S.; Wang, Y.L.; Murata-Hori, M. α-actinin is required for tightly regulated remodeling of the actin cortical network during cytokinesis. Dev. Cell 2007, 13, 554–565. [Google Scholar] [CrossRef]
  70. Feng, S.; Resendiz, J.C.; Christodoulides, N.; Lu, X.; Arboleda, D.; Berndt, M.C.; Kroll, M.H. Pathological shear stress stimulates the tyrosine phosphorylation of α-actinin associated with the glycoprotein Ib-IX complex. Biochemistry 2002, 41, 1100–1108. [Google Scholar] [CrossRef]
  71. Poulter, N.S.; Pollitt, A.Y.; Davies, A.; Malinova, D.; Nash, G.B.; Hannon, M.J.; Pikramenou, Z.; Rappoport, J.Z.; Hartwig, J.H.; Owen, D.M.; et al. Platelet actin nodules are podosome-like structures dependent on Wiskott-Aldrich syndrome protein and ARP2/3 complex. Nat. Commun. 2015, 6, 7254. [Google Scholar] [CrossRef]
  72. Lin, X.; Gao, H.; Xin, M.; Huang, J.; Li, X.; Zhou, Y.; Lv, K.; Huang, X.; Wang, J.; Zhou, Y.; et al. α-Actinin-1 deficiency in megakaryocytes causes low platelet count, platelet dysfunction, and mitochondrial impairment. Blood Adv. 2025, 9, 1185–1201. [Google Scholar] [CrossRef]
  73. Noureddine, M.; Mikolajek, H.; Morgan, N.V.; Denning, C.; Loughna, S.; Gehmlich, K.; Mohammed, F. Structural and functional insights into α-actinin isoforms and their implications in cardiovascular disease. J. Gen. Physiol. 2025, 157, e202413684. [Google Scholar] [CrossRef]
  74. Pinotsis, N.; Zielinska, K.; Babuta, M.; Arolas, J.L.; Kostan, J.; Khan, M.B.; Schreiner, C.; Salmazo, A.; Ciccarelli, L.; Puchinger, M.; et al. Calcium modulates the domain flexibility and function of an α-actinin similar to the ancestral α-actinin. Proc. Natl. Acad. Sci. USA 2020, 117, 22101–22112. [Google Scholar] [CrossRef]
  75. Sjoblom, B.; Salmazo, A.; Djinovic-Carugo, K. α-Actinin structure and regulation. Cell. Mol. Life Sci. 2008, 65, 2688–2701. [Google Scholar] [CrossRef]
  76. Murphy, A.C.; Lindsay, A.J.; McCaffrey, M.W.; Djinovic-Carugo, K.; Young, P.W. Congenital macrothrombocytopenia-linked mutations in the actin-binding domain of α-actinin-1 enhance F-actin association. FEBS Lett. 2016, 590, 685–695. [Google Scholar] [CrossRef] [PubMed]
  77. Murphy, A.C.; Young, P.W. The actinin family of actin cross-linking proteins—A genetic perspective. Cell Biosci. 2015, 5, 49. [Google Scholar] [CrossRef] [PubMed]
  78. Westbury, S.K.; Shoemark, D.K.; Mumford, A.D. ACTN1 variants associated with thrombocytopenia. Platelets 2017, 28, 625–627. [Google Scholar] [CrossRef] [PubMed]
  79. Izdebska, M.; Zielinska, W.; Halas-Wisniewska, M.; Grzanka, A. Involvement of actin and actin-binding proteins in carcinogenesis. Cells 2020, 9, 2245. [Google Scholar] [CrossRef]
  80. Oikonomou, K.G.; Zachou, K.; Dalekos, G.N. α-Actinin: A multidisciplinary protein with important role in B-cell driven autoimmunity. Autoimmun Rev. 2011, 10, 389–396. [Google Scholar] [CrossRef]
  81. Otey, C.A.; Vasquez, G.B.; Burridge, K.; Erickson, B.W. Mapping of the α-actinin binding site within the β1 integrin cytoplasmic domain. J. Biol. Chem. 1993, 268, 21193–21197. [Google Scholar] [CrossRef]
  82. Roca-Cusachs, P.; del Rio, A.; Puklin-Faucher, E.; Gauthier, N.C.; Biais, N.; Sheetz, M.P. Integrin-dependent force transmission to the extracellular matrix by α-actinin triggers adhesion maturation. Proc. Natl. Acad. Sci. USA 2013, 110, E1361–E1370. [Google Scholar] [CrossRef]
  83. Wang, R.; Gao, Y.; Zhang, H. ACTN1 interacts with ITGA5 to promote cell proliferation, invasion and epithelial-mesenchymal transformation in head and neck squamous cell carcinoma. Iran. J. Basic Med. Sci. 2023, 26, 200–207. [Google Scholar] [CrossRef] [PubMed]
  84. Collin, G.B.; Marshall, J.D.; King, B.L.; Milan, G.; Maffei, P.; Jagger, D.J.; Naggert, J.K. The Alstrom syndrome protein, ALMS1, interacts with α-actinin and components of the endosome recycling pathway. PLoS ONE 2012, 7, e37925. [Google Scholar] [CrossRef]
  85. Reinhard, M.; Zumbrunn, J.; Jaquemar, D.; Kuhn, M.; Walter, U.; Trueb, B. An α-actinin binding site of zyxin is essential for subcellular zyxin localization and α-actinin recruitment. J. Biol. Chem. 1999, 274, 13410–13418. [Google Scholar] [CrossRef] [PubMed]
  86. Bauer, K.; Kratzer, M.; Otte, M.; de Quintana, K.L.; Hagmann, J.; Arnold, G.J.; Eckerskorn, C.; Lottspeich, F.; Siess, W. Human CLP36, a PDZ-domain and LIM-domain protein, binds to α-actinin-1 and associates with actin filaments and stress fibers in activated platelets and endothelial cells. Blood 2000, 96, 4236–4245. [Google Scholar] [CrossRef] [PubMed]
  87. Eich, F.; Nonis, D.F.; Sen, N.-E.; Nowock, J.; Auburger, G. Ataxin-2 Binds α-Actinin-1. Preprints, 2019; 2019110399. [Google Scholar] [CrossRef]
  88. Merrill, M.A.; Malik, Z.; Akyol, Z.; Bartos, J.A.; Leonard, A.S.; Hudmon, A.; Shea, M.A.; Hell, J.W. Displacement of α-actinin from the NMDA receptor NR1 C0 domain By Ca2+/calmodulin promotes CaMKII binding. Biochemistry 2007, 46, 8485–8497. [Google Scholar] [CrossRef]
  89. Jahan, F.; Madhavan, S.; Rolova, T.; Viazmina, L.; Gronholm, M.; Gahmberg, C.G. Phosphorylation of the α-chain in the integrin LFA-1 enables β2-chain phosphorylation and α-actinin binding required for cell adhesion. J. Biol. Chem. 2018, 293, 12318–12330. [Google Scholar] [CrossRef]
  90. Stanley, P.; Smith, A.; McDowall, A.; Nicol, A.; Zicha, D.; Hogg, N. Intermediate-affinity LFA-1 binds α-actinin-1 to control migration at the leading edge of the T cell. EMBO J. 2008, 27, 62–75. [Google Scholar] [CrossRef]
  91. Le, S.; Hu, X.; Yao, M.; Chen, H.; Yu, M.; Xu, X.; Nakazawa, N.; Margadant, F.M.; Sheetz, M.P.; Yan, J. Mechanotransmission and mechanosensing of human α-actinin 1. Cell Rep. 2017, 21, 2714–2723. [Google Scholar] [CrossRef]
  92. Iyer, S.S.; Kusner, D.J. Association of phospholipase D activity with the detergent-insoluble cytoskeleton of U937 promonocytic leukocytes. J. Biol. Chem. 1999, 274, 2350–2359. [Google Scholar] [CrossRef]
  93. Park, J.B.; Kim, J.H.; Kim, Y.; Ha, S.H.; Yoo, J.S.; Du, G.; Frohman, M.A.; Suh, P.G.; Ryu, S.H. Cardiac phospholipase D2 localizes to sarcolemmal membranes and is inhibited by α-actinin in an ADP-ribosylation factor-reversible manner. J. Biol. Chem. 2000, 275, 21295–21301. [Google Scholar] [CrossRef]
  94. Chen, Q.; Zhou, X.W.; Zhang, A.J.; He, K. ACTN1 supports tumor growth by inhibiting Hippo signaling in hepatocellular carcinoma. J. Exp. Clin. Cancer Res. 2021, 40, 23. [Google Scholar] [CrossRef]
  95. Torii, T.; Miyamoto, Y.; Nakamura, K.; Maeda, M.; Yamauchi, J.; Tanoue, A. Arf6 guanine-nucleotide exchange factor, cytohesin-2, interacts with actinin-1 to regulate neurite extension. Cell Signal. 2012, 24, 1872–1882. [Google Scholar] [CrossRef]
  96. Milanini, J.; Fayad, R.; Partisani, M.; Lecine, P.; Borg, J.P.; Franco, M.; Luton, F. EFA6 proteins regulate lumen formation through α-actinin 1. J. Cell Sci. 2018, 131, jcs209361. [Google Scholar] [CrossRef]
  97. Turner, M.; Anderson, D.E.; Bartels, P.; Nieves-Cintron, M.; Coleman, A.M.; Henderson, P.B.; Man, K.N.M.; Tseng, P.Y.; Yarov-Yarovoy, V.; Bers, D.M.; et al. α-Actinin-1 promotes activity of the L-type Ca2+ channel Cav1.2. EMBO J. 2020, 39, e102622. [Google Scholar] [CrossRef]
  98. Li, Q.; Montalbetti, N.; Shen, P.Y.; Dai, X.Q.; Cheeseman, C.I.; Karpinski, E.; Wu, G.; Cantiello, H.F.; Chen, X.Z. α-Actinin associates with polycystin-2 and regulates its channel activity. Hum. Mol. Genet. 2005, 14, 1587–1603. [Google Scholar] [CrossRef] [PubMed]
  99. Li, Q.; Dai, X.Q.; Shen, P.Y.; Wu, Y.; Long, W.; Chen, C.X.; Hussain, Z.; Wang, S.; Chen, X.Z. Direct binding of α-actinin enhances TRPP3 channel activity. J. Neurochem. 2007, 103, 2391–2400. [Google Scholar] [CrossRef] [PubMed]
  100. Cabello, N.; Remelli, R.; Canela, L.; Soriguera, A.; Mallol, J.; Canela, E.I.; Robbins, M.J.; Lluis, C.; Franco, R.; McIlhinney, R.A.; et al. Actin-binding protein α-actinin-1 interacts with the metabotropic glutamate receptor type 5b and modulates the cell surface expression and function of the receptor. J. Biol. Chem. 2007, 282, 12143–12153. [Google Scholar] [CrossRef] [PubMed]
  101. Christerson, L.B.; Vanderbilt, C.A.; Cobb, M.H. MEKK1 interacts with α-actinin and localizes to stress fibers and focal adhesions. Cell Motil. 1999, 43, 186–198. [Google Scholar] [CrossRef]
  102. Cao, Y.; Cao, W.; Qiu, Y.; Zhou, Y.; Guo, Q.; Gao, Y.; Lu, N. Oroxylin A suppresses ACTN1 expression to inactivate cancer-associated fibroblasts and restrain breast cancer metastasis. Pharmacol. Res. 2020, 159, 104981. [Google Scholar] [CrossRef] [PubMed]
  103. Hynes, R.O. Integrins: Bidirectional, allosteric signaling machines. Cell 2002, 110, 673–687. [Google Scholar] [CrossRef] [PubMed]
  104. Durrant, T.N.; van den Bosch, M.T.; Hers, I. Integrin αIIbβ3 outside-in signaling. Blood 2017, 130, 1607–1619. [Google Scholar] [CrossRef]
  105. Antenucci, L.; Hytonen, V.P.; Ylanne, J. Phosphorylated immunoreceptor tyrosine-based activation motifs and integrin cytoplasmic domains activate spleen tyrosine kinase via distinct mechanisms. J. Biol. Chem. 2018, 293, 4591–4602. [Google Scholar] [CrossRef]
  106. Bury, L.; Malara, A.; Gresele, P.; Balduini, A. Outside-in signalling generated by a constitutively activated integrin αIIbβ3 impairs proplatelet formation in human megakaryocytes. PLoS ONE 2012, 7, e34449. [Google Scholar] [CrossRef]
  107. Bennett, J.S. Structure and function of the platelet integrin αIIbβ3. J. Clin. Investig. 2005, 115, 3363–3369. [Google Scholar] [CrossRef]
  108. Coller, B.S. αIIbβ3: Structure and function. J. Thromb. Haemost. 2015, 13 (Suppl. S1), S17–S25. [Google Scholar] [CrossRef]
  109. Tao, L.; Zhang, Y.; Xi, X.; Kieffer, N. Recent advances in the understanding of the molecular mechanisms regulating platelet integrin αIIbβ3 activation. Protein Cell 2010, 1, 627–637. [Google Scholar] [CrossRef]
  110. Xin, H.; Huang, J.; Song, Z.; Mao, J.; Xi, X.; Shi, X. Structure, signal transduction, activation, and inhibition of integrin αIIbβ3. Thromb. J. 2023, 21, 18. [Google Scholar] [CrossRef]
  111. Deshmukh, L.; Gorbatyuk, V.; Vinogradova, O. Integrin β3 phosphorylation dictates its complex with the Shc phosphotyrosine-binding (PTB) domain. J. Biol. Chem. 2010, 285, 34875–34884. [Google Scholar] [CrossRef] [PubMed]
  112. Gahmberg, C.G.; Gronholm, M.; Uotila, L.M. Regulation of integrin activity by phosphorylation. Adv. Exp. Med. Biol. 2014, 819, 85–96. [Google Scholar] [PubMed]
  113. Kirk, R.I.; Sanderson, M.R.; Lerea, K.M. Threonine phosphorylation of the β3 integrin cytoplasmic tail, at a site recognized by PDK1 and Akt/PKB in vitro, regulates Shc binding. J. Biol. Chem. 2000, 275, 30901–30906. [Google Scholar] [CrossRef]
  114. Xiang, B.; Zhang, G.; Ye, S.; Zhang, R.; Huang, C.; Liu, J.; Tao, M.; Ruan, C.; Smyth, S.S.; Whiteheart, S.W.; et al. Characterization of a novel integrin binding protein, VPS33B, which is important for platelet activation and in vivo thrombosis and hemostasis. Circulation 2015, 132, 2334–2344. [Google Scholar] [CrossRef]
  115. Rodius, S.; Chaloin, O.; Moes, M.; Schaffner-Reckinger, E.; Landrieu, I.; Lippens, G.; Lin, M.; Zhang, J.; Kieffer, N. The talin rod IBS2 α-helix interacts with the β3 integrin cytoplasmic tail membrane-proximal helix by establishing charge complementary salt bridges. J. Biol. Chem. 2008, 283, 24212–24223. [Google Scholar] [CrossRef] [PubMed]
  116. Huang, J.; Shi, X.; Xi, W.; Liu, P.; Long, Z.; Xi, X. Evaluation of targeting c-Src by the RGT-containing peptide as a novel antithrombotic strategy. J. Hematol. Oncol. 2015, 8, 62. [Google Scholar] [CrossRef]
  117. Su, X.; Mi, J.; Yan, J.; Flevaris, P.; Lu, Y.; Liu, H.; Ruan, Z.; Wang, X.; Kieffer, N.; Chen, S.; et al. RGT, a synthetic peptide corresponding to the integrin β3 cytoplasmic C-terminal sequence, selectively inhibits outside-in signaling in human platelets by disrupting the interaction of integrin αIIbβ3 with Src kinase. Blood 2008, 112, 592–602. [Google Scholar] [CrossRef]
  118. Gong, H.; Shen, B.; Flevaris, P.; Chow, C.; Lam, S.C.; Voyno-Yasenetskaya, T.A.; Kozasa, T.; Du, X. G protein subunit Gα13 binds to integrin αIIbβ3 and mediates integrin “outside-in” signaling. Science 2010, 327, 340–343. [Google Scholar] [CrossRef]
  119. Shen, B.; Zhao, X.; O’Brien, K.A.; Stojanovic-Terpo, A.; Delaney, M.K.; Kim, K.; Cho, J.; Lam, S.C.; Du, X. A directional switch of integrin signalling and a new anti-thrombotic strategy. Nature 2013, 503, 131–135. [Google Scholar] [CrossRef]
  120. Honda, S.; Shirotani-Ikejima, H.; Tadokoro, S.; Maeda, Y.; Kinoshita, T.; Tomiyama, Y.; Miyata, T. Integrin-linked kinase associated with integrin activation. Blood 2009, 113, 5304–5313. [Google Scholar] [CrossRef]
  121. Eigenthaler, M.; Hofferer, L.; Shattil, S.J.; Ginsberg, M.H. A conserved sequence motif in the integrin β3 cytoplasmic domain is required for its specific interaction with β3-endonexin. J. Biol. Chem. 1997, 272, 7693–7698. [Google Scholar] [CrossRef]
  122. Goult, B.T.; Bouaouina, M.; Elliott, P.R.; Bate, N.; Patel, B.; Gingras, A.R.; Grossmann, J.G.; Roberts, G.C.; Calderwood, D.A.; Critchley, D.R.; et al. Structure of a double ubiquitin-like domain in the talin head: A role in integrin activation. EMBO J. 2010, 29, 1069–1080. [Google Scholar] [CrossRef] [PubMed]
  123. Harburger, D.S.; Bouaouina, M.; Calderwood, D.A. Kindlin-1 and -2 directly bind the C-terminal region of β integrin cytoplasmic tails and exert integrin-specific activation effects. J. Biol. Chem. 2009, 284, 11485–11497. [Google Scholar] [CrossRef] [PubMed]
  124. Legate, K.R.; Fassler, R. Mechanisms that regulate adaptor binding to β-integrin cytoplasmic tails. J. Cell Sci. 2009, 122, 187–198. [Google Scholar] [CrossRef] [PubMed]
  125. Lyman, S.; Gilmore, A.; Burridge, K.; Gidwitz, S.; White, G.C., II. Integrin-mediated activation of focal adhesion kinase is independent of focal adhesion formation or integrin activation. Studies with activated and inhibitory β3 cytoplasmic domain mutants. J. Biol. Chem. 1997, 272, 22538–22547. [Google Scholar]
  126. Tadokoro, S.; Nakazawa, T.; Kamae, T.; Kiyomizu, K.; Kashiwagi, H.; Honda, S.; Kanakura, Y.; Tomiyama, Y. A potential role for α-actinin in inside-out αIIbβ3 signaling. Blood 2011, 117, 250–258. [Google Scholar]
  127. Feng, S.; Lu, X.; Resendiz, J.C.; Kroll, M.H. Pathological shear stress directly regulates platelet αIIbβ3 signaling. Am. J. Physiol. Cell Physiol. 2006, 291, C1346–C1354. [Google Scholar] [CrossRef]
  128. Shams, H.; Mofrad, M.R.K. α-Actinin induces a kink in the transmembrane domain of β3-integrin and impairs activation via talin. Biophys. J. 2017, 113, 948–956. [Google Scholar] [CrossRef]
  129. Yan, B.; Calderwood, D.A.; Yaspan, B.; Ginsberg, M.H. Calpain cleavage promotes talin binding to the β3 integrin cytoplasmic domain. J. Biol. Chem. 2001, 276, 28164–28170. [Google Scholar] [CrossRef]
  130. Critchley, D.R.; Gingras, A.R. Talin at a glance. J. Cell Sci. 2008, 121, 1345–1347. [Google Scholar] [CrossRef]
  131. Favier, M.; Bordet, J.C.; Favier, R.; Gkalea, V.; Pillois, X.; Rameau, P.; Debili, N.; Alessi, M.C.; Nurden, P.; Raslova, H.; et al. Mutations of the integrin αIIbβ3 intracytoplasmic salt bridge cause macrothrombocytopenia and enlarged platelet α-granules. Am. J. Hematol. 2018, 93, 195–204. [Google Scholar] [CrossRef]
  132. Ghevaert, C.; Salsmann, A.; Watkins, N.A.; Schaffner-Reckinger, E.; Rankin, A.; Garner, S.F.; Stephens, J.; Smith, G.A.; Debili, N.; Vainchenker, W.; et al. A nonsynonymous SNP in the ITGB3 gene disrupts the conserved membrane-proximal cytoplasmic salt bridge in the αIIbβ3 integrin and cosegregates dominantly with abnormal proplatelet formation and macrothrombocytopenia. Blood 2008, 111, 3407–3414. [Google Scholar] [CrossRef]
  133. Kunishima, S.; Kashiwagi, H.; Otsu, M.; Takayama, N.; Eto, K.; Onodera, M.; Miyajima, Y.; Takamatsu, Y.; Suzumiya, J.; Matsubara, K.; et al. Heterozygous ITGA2B R995W mutation inducing constitutive activation of the αIIbβ3 receptor affects proplatelet formation and causes congenital macrothrombocytopenia. Blood 2011, 117, 5479–5484. [Google Scholar] [CrossRef] [PubMed]
  134. Pillois, X.; Guy, A.; Choquet, E.; James, C.; Tuffigo, M.; Viallard, J.F.; Garcia, C.; Bordet, J.C.; Jandrot-Perrus, M.; Payrastre, B.; et al. First description of an IgM monoclonal antibody causing αIIbβ3 integrin activation and acquired Glanzmann thrombasthenia associated with macrothrombocytopenia. J. Thromb. Haemost. 2019, 17, 795–802. [Google Scholar] [CrossRef] [PubMed]
  135. Donada, A.; Balayn, N.; Sliwa, D.; Lordier, L.; Ceglia, V.; Baschieri, F.; Goizet, C.; Favier, R.; Tosca, L.; Tachdjian, G.; et al. Disrupted filamin A/αIIbβ3 interaction induces macrothrombocytopenia by increasing RhoA activity. Blood 2019, 133, 1778–1788. [Google Scholar] [CrossRef] [PubMed]
  136. Molina-Ortiz, P.; Polizzi, S.; Ramery, E.; Gayral, S.; Delierneux, C.; Oury, C.; Iwashita, S.; Schurmans, S. Rasa3 controls megakaryocyte Rap1 activation, integrin signaling and differentiation into proplatelet. PLoS Genet. 2014, 10, e1004420. [Google Scholar] [CrossRef]
  137. Jarocha, D.; Vo, K.K.; Lyde, R.B.; Hayes, V.; Camire, R.M.; Poncz, M. Enhancing functional platelet release in vivo from in vitro-grown megakaryocytes using small molecule inhibitors. Blood Adv. 2018, 2, 597–606. [Google Scholar] [CrossRef]
  138. Franzot, G.; Sjoblom, B.; Gautel, M.; Djinovic Carugo, K. The crystal structure of the actin binding domain from α-actinin in its closed conformation: Structural insight into phospholipid regulation of α-actinin. J. Mol. Biol. 2005, 348, 151–165. [Google Scholar] [CrossRef]
  139. Yan, R.; Ge, X.; Pang, N.; Ye, H.; Yuan, L.; Cheng, B.; Zhou, K.; Yang, M.; Sun, Y.; Zhang, S.; et al. Essential role of zyxin in platelet biogenesis and glycoprotein Ib-IX surface expression. Cell Death Dis. 2021, 12, 955. [Google Scholar] [CrossRef]
  140. Sampath, R.; Gallagher, P.J.; Pavalko, F.M. Cytoskeletal interactions with the leukocyte integrin β2 cytoplasmic tail. Activation-dependent regulation of associations with talin and α-actinin. J. Biol. Chem. 1998, 273, 33588–33594. [Google Scholar] [CrossRef]
  141. Pavalko, F.M.; LaRoche, S.M. Activation of human neutrophils induces an interaction between the integrin β2-subunit (CD18) and the actin binding protein α-actinin. J. Immunol. 1993, 151, 3795–3807. [Google Scholar] [CrossRef]
  142. Gahmberg, C.G.; Gronholm, M. How integrin phosphorylations regulate cell adhesion and signaling. Trends Biochem. Sci. 2022, 47, 265–278. [Google Scholar] [CrossRef]
  143. Fox, N.E.; Kaushansky, K. Engagement of integrin α4β1 enhances thrombopoietin-induced megakaryopoiesis. Exp. Hematol. 2005, 33, 94–99. [Google Scholar] [CrossRef] [PubMed]
  144. Matsuura, S.; Thompson, C.R.; Ng, S.K.; Ward, C.M.; Karagianni, A.; Mazzeo, C.; Malara, A.; Balduini, A.; Ravid, K. Adhesion to fibronectin via α5β1 integrin supports expansion of the megakaryocyte lineage in primary myelofibrosis. Blood 2020, 135, 2286–2291. [Google Scholar] [CrossRef]
  145. Mazzarini, M.; Verachi, P.; Martelli, F.; Migliaccio, A.R. Role of β1 integrin in thrombocytopoiesis. Fac. Rev. 2021, 10, 68. [Google Scholar] [CrossRef]
  146. Zou, Z.; Schmaier, A.A.; Cheng, L.; Mericko, P.; Dickeson, S.K.; Stricker, T.P.; Santoro, S.A.; Kahn, M.L. Negative regulation of activated α2 integrins during thrombopoiesis. Blood 2009, 113, 6428–6439. [Google Scholar] [CrossRef]
  147. Habart, D.; Cheli, Y.; Nugent, D.J.; Ruggeri, Z.M.; Kunicki, T.J. Conditional knockout of integrin α2β1 in murine megakaryocytes leads to reduced mean platelet volume. PLoS ONE 2013, 8, e55094. [Google Scholar] [CrossRef]
  148. Stritt, S.; Thielmann, I.; Dutting, S.; Stegner, D.; Nieswandt, B. Phospholipase D is a central regulator of collagen I-induced cytoskeletal rearrangement and podosome formation in megakaryocytes. J. Thromb. Haemost. 2014, 12, 1364–1371. [Google Scholar] [CrossRef]
  149. Bolomini-Vittori, M.; Mennens, S.F.B.; Joosten, B.; Fransen, J.; Du, G.; van den Dries, K.; Cambi, A. PLD-dependent phosphatidic acid microdomains are signaling platforms for podosome formation. Sci. Rep. 2019, 9, 3556. [Google Scholar] [CrossRef] [PubMed]
  150. Kam, Y.; Exton, J.H. Phospholipase D activity is required for actin stress fiber formation in fibroblasts. Mol. Cell. Biol. 2001, 21, 4055–4066. [Google Scholar] [CrossRef] [PubMed]
  151. Bolomini-Vittori, M.; Montresor, A.; Giagulli, C.; Staunton, D.; Rossi, B.; Martinello, M.; Constantin, G.; Laudanna, C. Regulation of conformer-specific activation of the integrin LFA-1 by a chemokine-triggered Rho signaling module. Nat. Immunol. 2009, 10, 185–194. [Google Scholar] [CrossRef]
  152. Chen, C.; Wang, N.; Zhang, X.; Fu, Y.; Zhong, Z.; Wu, H.; Wei, Y.; Duan, Y. Highly efficient generation of mature megakaryocytes and functional platelets from human embryonic stem cells. Stem Cell Res. Ther. 2024, 15, 454. [Google Scholar] [CrossRef]
  153. Jin, J.; Zhang, L.; Li, X.; Xu, W.; Yang, S.; Song, J.; Zhang, W.; Zhan, J.; Luo, J.; Zhang, H. Oxidative stress-CBP axis modulates MOB1 acetylation and activates the Hippo signaling pathway. Nucleic Acids Res. 2022, 50, 3817–3834. [Google Scholar] [CrossRef]
  154. Lorthongpanich, C.; Jiamvoraphong, N.; Klaihmon, P.; Lueangamornnara, U.; U-Pratya, Y.; Laowtammathron, C.; Issaragrisil, S. Effect of YAP/TAZ on megakaryocyte differentiation and platelet production. Biosci. Rep. 2020, 40, BSR20201780. [Google Scholar] [CrossRef]
  155. Lorthongpanich, C.; Jiamvoraphong, N.; Supraditaporn, K.; Klaihmon, P.; U-Pratya, Y.; Issaragrisil, S. The Hippo pathway regulates human megakaryocytic differentiation. Thromb. Haemost. 2017, 117, 116–126. [Google Scholar] [CrossRef] [PubMed]
  156. Florindo, C.; Perdigao, J.; Fesquet, D.; Schiebel, E.; Pines, J.; Tavares, A.A. Human Mob1 proteins are required for cytokinesis by controlling microtubule stability. J. Cell Sci. 2012, 125, 3085–3090. [Google Scholar] [CrossRef] [PubMed]
  157. Bennett, C.; Lawrence, M.; Guerrero, J.A.; Stritt, S.; Waller, A.K.; Yan, Y.; Mifsud, R.W.; Ballester-Beltran, J.; Baig, A.; Mueller, A.; et al. CRLF3 plays a key role in the final stage of platelet genesis and is a potential therapeutic target for thrombocythemia. Blood 2022, 139, 2227–2239. [Google Scholar] [CrossRef]
  158. Ito, H.; Morishita, R.; Noda, M.; Ishiguro, T.; Nishikawa, M.; Nagata, K.I. The synaptic scaffolding protein CNKSR2 interacts with CYTH2 to mediate hippocampal granule cell development. J. Biol. Chem. 2021, 297, 101427. [Google Scholar] [CrossRef]
  159. van den Bosch, M.T.; Poole, A.W.; Hers, I. Cytohesin-2 phosphorylation by protein kinase C relieves the constitutive suppression of platelet dense granule secretion by ADP-ribosylation factor 6. J. Thromb. Haemost. 2014, 12, 726–735. [Google Scholar] [CrossRef] [PubMed]
  160. Nyman-Huttunen, H.; Tian, L.; Ning, L.; Gahmberg, C.G. α-Actinin-dependent cytoskeletal anchorage is important for ICAM-5-mediated neuritic outgrowth. J. Cell Sci. 2006, 119, 3057–3066. [Google Scholar]
  161. Derrien, V.; Couillault, C.; Franco, M.; Martineau, S.; Montcourrier, P.; Houlgatte, R.; Chavrier, P. A conserved C-terminal domain of EFA6-family ARF6-guanine nucleotide exchange factors induces lengthening of microvilli-like membrane protrusions. J. Cell Sci. 2002, 115, 2867–2879. [Google Scholar] [CrossRef]
  162. Franssen, E.H.; Zhao, R.R.; Koseki, H.; Kanamarlapudi, V.; Hoogenraad, C.C.; Eva, R.; Fawcett, J.W. Exclusion of integrins from CNS axons is regulated by Arf6 activation and the AIS. J. Neurosci. 2015, 35, 8359–8375. [Google Scholar] [CrossRef] [PubMed]
  163. Li, M.; Ng, S.S.; Wang, J.; Lai, L.; Leung, S.Y.; Franco, M.; Peng, Y.; He, M.L.; Kung, H.F.; Lin, M.C. EFA6A enhances glioma cell invasion through ADP ribosylation factor 6/extracellular signal-regulated kinase signaling. Cancer Res. 2006, 66, 1583–1590. [Google Scholar]
  164. Chomphoo, S.; Sakagami, H.; Kondo, H.; Hipkaeo, W. Localization of EFA6A, an exchange factor for Arf6, in Z-lines and sarcoplasmic reticulum membranes in addition to myofilaments in I-domains of skeletal myofibers of peri-natal mice. Acta Histochem. 2024, 126, 152187. [Google Scholar]
  165. Ostrowski, L.A.; Hall, A.C.; Mekhail, K. Ataxin-2: From RNA control to human health and disease. Genes 2017, 8, 157. [Google Scholar] [CrossRef]
  166. Amado, D.A.; Robbins, A.B.; Whiteman, K.R.; Smith, A.R.; Chillon, G.; Chen, Y.; Fuller, J.A.; Patty, N.A.; Izda, A.; Cheng, C.; et al. AAV-based delivery of RNAi targeting ataxin-2 improves survival and pathology in TDP-43 mice. Nat. Commun. 2025, 16, 5334. [Google Scholar] [CrossRef] [PubMed]
  167. Yokoshi, M.; Li, Q.; Yamamoto, M.; Okada, H.; Suzuki, Y.; Kawahara, Y. Direct binding of Ataxin-2 to distinct elements in 3’ UTRs promotes mRNA stability and protein expression. Mol. Cell 2014, 55, 186–198. [Google Scholar] [CrossRef]
  168. Ochoa, E.; Iriondo, M.; Bielsa, A.; Ruiz-Irastorza, G.; Estonba, A.; Zubiaga, A.M. Thrombotic antiphospholipid syndrome shows strong haplotypic association with SH2B3-ATXN2 locus. PLoS ONE 2013, 8, e67897. [Google Scholar]
  169. Hansen, M.; Zeddies, S.; Meinders, M.; di Summa, F.; van Alphen, F.P.J.; Hoogendijk, A.J.; Moore, K.S.; Halbach, M.; Gutierrez, L.; van den Biggelaar, M.; et al. The RNA-binding protein ATXN2 is expressed during megakaryopoiesis and may control timing of gene expression. Int. J. Mol. Sci. 2020, 21, 967. [Google Scholar] [CrossRef]
  170. Gimona, M.; Djinovic-Carugo, K.; Kranewitter, W.J.; Winder, S.J. Functional plasticity of CH domains. FEBS Lett. 2002, 513, 98–106. [Google Scholar] [PubMed]
  171. Sjoblom, B.; Ylanne, J.; Djinovic-Carugo, K. Novel structural insights into F-actin-binding and novel functions of calponin homology domains. Curr. Opin. Struct. Biol. 2008, 18, 702–708. [Google Scholar] [CrossRef]
  172. Neu, C.T.; Gutschner, T.; Haemmerle, M. Post-transcriptional expression control in platelet biogenesis and function. Int. J. Mol. Sci. 2020, 21, 7614. [Google Scholar] [CrossRef]
  173. Matsui, M.; Bouchareb, R.; Storto, M.; Hussain, Y.; Gregg, A.; Marx, S.O.; Pitt, G.S. Increased Ca2+ influx through CaV1.2 drives aortic valve calcification. JCI Insight 2022, 7, e155569. [Google Scholar] [CrossRef]
  174. Backman, L. Calcium affinity of human α-actinin 1. PeerJ 2015, 3, e944. [Google Scholar] [CrossRef]
  175. Maruoka, N.D.; Steele, D.F.; Au, B.P.; Dan, P.; Zhang, X.; Moore, E.D.; Fedida, D. α-Actinin-2 couples to cardiac Kv1.5 channels, regulating current density and channel localization in HEK cells. FEBS Lett. 2000, 473, 188–194. [Google Scholar] [CrossRef] [PubMed]
  176. Wei, Y.; Yu, Z.; Wang, L.; Li, X.; Li, N.; Bai, Q.; Wang, Y.; Li, R.; Meng, Y.; Xu, H.; et al. Structural bases of inhibitory mechanism of Ca(V)1.2 channel inhibitors. Nat. Commun. 2024, 15, 2772. [Google Scholar] [CrossRef]
  177. Ajanel, A.; Andrianova, I.; Kowalczyk, M.; Menendez-Perez, J.; Bhatt, S.R.; Portier, I.; Boone, T.C.; Ballard-Kordeliski, A.; Kosaka, Y.; Chaudhuri, D.; et al. Mitochondrial Calcium Uniporter Regulates ITAM-Dependent Platelet Activation. Circ. Res. 2025, 137, 474–492. [Google Scholar] [CrossRef] [PubMed]
  178. Shehwar, D.; Barki, S.; Aliotta, A.; Calderara, D.B.; Veuthey, L.; Portela, C.P.; Alberio, L.; Alam, M.R. Platelets and mitochondria: The calcium connection. Mol. Biol. Rep. 2025, 52, 276. [Google Scholar] [CrossRef] [PubMed]
  179. Di Buduo, C.A.; Abbonante, V.; Marty, C.; Moccia, F.; Rumi, E.; Pietra, D.; Soprano, P.M.; Lim, D.; Cattaneo, D.; Iurlo, A.; et al. Defective interaction of mutant calreticulin and SOCE in megakaryocytes from patients with myeloproliferative neoplasms. Blood 2020, 135, 133–144. [Google Scholar] [CrossRef]
  180. Yashiro, K.; Philpot, B.D. Regulation of NMDA receptor subunit expression and its implications for LTD, LTP, and metaplasticity. Neuropharmacology 2008, 55, 1081–1094. [Google Scholar] [CrossRef]
  181. Genever, P.G.; Wilkinson, D.J.; Patton, A.J.; Peet, N.M.; Hong, Y.; Mathur, A.; Erusalimsky, J.D.; Skerry, T.M. Expression of a functional N-methyl-D-aspartate-type glutamate receptor by bone marrow megakaryocytes. Blood 1999, 93, 2876–2883. [Google Scholar] [CrossRef] [PubMed]
  182. Hitchcock, I.S.; Skerry, T.M.; Howard, M.R.; Genever, P.G. NMDA receptor-mediated regulation of human megakaryocytopoiesis. Blood 2003, 102, 1254–1259. [Google Scholar] [CrossRef]
  183. Hearn, J.I.; Green, T.N.; Hisey, C.L.; Bender, M.; Josefsson, E.C.; Knowlton, N.; Baumann, J.; Poulsen, R.C.; Bohlander, S.K.; Kalev-Zylinska, M.L. Deletion of Grin1 in mouse megakaryocytes reveals NMDA receptor role in platelet function and proplatelet formation. Blood 2022, 139, 2673–2690. [Google Scholar] [CrossRef]
  184. Wang, S.; Wang, X.; Pan, C.; Liu, Y.; Lei, M.; Guo, X.; Chen, Q.; Yang, X.; Ouyang, C.; Ren, Z. Functions of actin-binding proteins in cilia structure remodeling and signaling. Biol. Cell 2023, 115, e202300026. [Google Scholar] [CrossRef] [PubMed]
  185. Ku, S.K.; Lee, I.C.; Bae, J.S. Antithrombotic activities of oroxylin A in vitro and in vivo. Arch. Pharm. Res. 2014, 37, 679–686. [Google Scholar] [CrossRef] [PubMed]
Biomedicines 13 02479 g001
Figure 1. Schematic of the process of megakaryocyte (MK) maturation, polyploidization, and platelet production. In the bone marrow (BM), classical model, hematopoietic stem cells are induced by thrombopoietin (TPO)/c-Mpl signaling and undergo multiple rounds of endomitosis to achieve polyploidization. Concurrently, mitochondria provide energy for rapid cytoplasmic expansion, ultimately leading to differentiation into mature MKs. Under the coordinated action of cytokines such as stromal cell-derived factor-1α (SDF-1α) and fibroblast growth factor-4 (FGF-4), mature MKs migrate to sinusoidal capillaries rich in blood vessels. An alternative model suggesting the presence of MK/platelet-biased HSCs within the HSC population. Under the influence of blood flow shear stress, proplatelets extending from mature MKs are released into the circulating blood, where they become functional platelets.
Figure 1. Schematic of the process of megakaryocyte (MK) maturation, polyploidization, and platelet production. In the bone marrow (BM), classical model, hematopoietic stem cells are induced by thrombopoietin (TPO)/c-Mpl signaling and undergo multiple rounds of endomitosis to achieve polyploidization. Concurrently, mitochondria provide energy for rapid cytoplasmic expansion, ultimately leading to differentiation into mature MKs. Under the coordinated action of cytokines such as stromal cell-derived factor-1α (SDF-1α) and fibroblast growth factor-4 (FGF-4), mature MKs migrate to sinusoidal capillaries rich in blood vessels. An alternative model suggesting the presence of MK/platelet-biased HSCs within the HSC population. Under the influence of blood flow shear stress, proplatelets extending from mature MKs are released into the circulating blood, where they become functional platelets.
Biomedicines 13 02479 g001
Biomedicines 13 02479 g002
Figure 2. Schematic diagram of the α-actinin-1 dimer. The α-actinin-1 monomer consists of three conserved domains: the N-terminal actin-binding domain (ABD), which is composed of two CH (calponin homology) subdomains; the central rod domain, which is made up of four spectrin-like repeat (R) subdomains; and the C-terminal calmodulin (CaM) domain, which contains two Ca2+-binding E-helix and F-helix (EF)-hand subdomains. Two identical monomers assemble in an antiparallel manner to form an α-actinin-1 dimer.
Figure 2. Schematic diagram of the α-actinin-1 dimer. The α-actinin-1 monomer consists of three conserved domains: the N-terminal actin-binding domain (ABD), which is composed of two CH (calponin homology) subdomains; the central rod domain, which is made up of four spectrin-like repeat (R) subdomains; and the C-terminal calmodulin (CaM) domain, which contains two Ca2+-binding E-helix and F-helix (EF)-hand subdomains. Two identical monomers assemble in an antiparallel manner to form an α-actinin-1 dimer.
Biomedicines 13 02479 g002
Table 1. Binding partners of α-actinin-1 with known roles in megakaryocytes and platelets.
Table 1. Binding partners of α-actinin-1 with known roles in megakaryocytes and platelets.
Binding PartnersExperimentsDomain of α-Actinin-1References
Integrin β1Affinity chromatography, solid-phase binding, peptide-pin, and pull-down assaysRod domain[81,82]
Integrin β3Pull-down assays, immunoprecipitationSpectrin-like repeats 1–2[82]
Integrin α5CoimmunoprecipitationNA[83]
ActinImmunoprecipitation,Actin-binding Domain[81,82,84]
ZyxinBlot overlay assays, solid phase binding assaysN-terminal domain[85]
CLP36Coimmunoprecipitation, pull-down, and yeast two-hybridSpectrin-like repeats 2–3[86]
Ataxin-2GST-tag pull-downCalponin homology domain[87]
NMDA receptorsGST pull-downCalmodulin domain[88]
Table 2. Binding partners of α-actinin-1 with unknown roles in megakaryocytes and platelets.
Table 2. Binding partners of α-actinin-1 with unknown roles in megakaryocytes and platelets.
Binding PartnersExperimentsDomain of α-Actinin-1References
Integrin β2Solid phase binding assays, affinity chromatography experiments, and immunoprecipitationRod domain[89,90]
VinculinMagnetic tweezersRod domain[81,91]
PLDPLD2 overlay assay, in vitro binding assayN-terminal domain[92,93]
MOB1Coimmunoprecipitation, immunofluorescenceNA[94]
CYTH2CoimmunoprecipitationEFh1 and EFh2 domains[95]
EFA6Two-hybrid screen, GST pull-downSpectrin-like repeats[96]
CaV1.2NMR spectroscopy, fluorescence polarization assays, and cell surface biotinylation assaysEF3/4 domain[97]
PC-2 and 3Yeast two-hybrid, coimmunoprecipitation, and in vitro binding assaysSpectrin-like repeats[98,99]
mGlu5b receptorYeast two-hybrid, GST pull-down, and immunoprecipitation816–892 aa[100]
ALMS1Yeast two-hybridSpectrin-like repeats, EF hand[84]
MEKK1Yeast two-hybrid, immunoprecipitation371–892 aa[101]
Oroxylin ACellular thermal shift assay, drug affinity responsive target stability, and molecular dockingCalponin homology domain[102]
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.

Share and Cite

MDPI and ACS Style

Wu, L.; Song, Z.; Zhou, Y.; Huang, J.; Huang, X. α-Actinin-1 in Megakaryocytes: Its Structure, Interacting Proteins and Implications for Thrombopoiesis. Biomedicines 2025, 13, 2479. https://doi.org/10.3390/biomedicines13102479

AMA Style

Wu L, Song Z, Zhou Y, Huang J, Huang X. α-Actinin-1 in Megakaryocytes: Its Structure, Interacting Proteins and Implications for Thrombopoiesis. Biomedicines. 2025; 13(10):2479. https://doi.org/10.3390/biomedicines13102479

Chicago/Turabian Style

Wu, Lanlan, Zhiqun Song, Yulan Zhou, Jiansong Huang, and Xiaoxia Huang. 2025. "α-Actinin-1 in Megakaryocytes: Its Structure, Interacting Proteins and Implications for Thrombopoiesis" Biomedicines 13, no. 10: 2479. https://doi.org/10.3390/biomedicines13102479

APA Style

Wu, L., Song, Z., Zhou, Y., Huang, J., & Huang, X. (2025). α-Actinin-1 in Megakaryocytes: Its Structure, Interacting Proteins and Implications for Thrombopoiesis. Biomedicines, 13(10), 2479. https://doi.org/10.3390/biomedicines13102479

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop